0001695473 2026-01-01 2026-06-30 0001695473 2026-08-14 0001695473 2026-06-30 0001695473 2025-12-31 0001695473 us-gaap:RelatedPartyMember 2026-06-30 0001695473 us-gaap:RelatedPartyMember 2025-12-31 0001695473 GCAN:SeriesAConvertiblePreferredStockMember 2026-06-30 0001695473 GCAN:SeriesAConvertiblePreferredStockMember 2025-12-31 0001695473 GCAN:SeriesBConvertiblePreferredStockMember 2026-06-30 0001695473 GCAN:SeriesBConvertiblePreferredStockMember 2025-12-31 0001695473 2025-01-01 2025-12-31 0001695473 2026-04-01 2026-06-30 0001695473 2025-04-01 2025-06-30 0001695473 us-gaap:ProductMember 2026-04-01 2026-06-30 0001695473 us-gaap:ProductMember 2025-04-01 2025-06-30 0001695473 GCAN:ConsultingFeesMember 2026-04-01 2026-06-30 0001695473 GCAN:ConsultingFeesMember 2025-04-01 2025-06-30 0001695473 2025-01-01 2025-06-30 0001695473 us-gaap:ProductMember 2026-01-01 2026-06-30 0001695473 us-gaap:ProductMember 2025-01-01 2025-06-30 0001695473 GCAN:ConsultingFeesMember 2026-01-01 2026-06-30 0001695473 GCAN:ConsultingFeesMember 2025-01-01 2025-06-30 0001695473 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-12-31 0001695473 us-gaap:CommonStockMember 2024-12-31 0001695473 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001695473 us-gaap:RetainedEarningsMember 2024-12-31 0001695473 2024-12-31 0001695473 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-01-01 2025-03-31 0001695473 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001695473 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001695473 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001695473 2025-01-01 2025-03-31 0001695473 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-03-31 0001695473 us-gaap:CommonStockMember 2025-03-31 0001695473 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001695473 us-gaap:RetainedEarningsMember 2025-03-31 0001695473 2025-03-31 0001695473 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-04-01 2025-06-30 0001695473 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001695473 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001695473 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001695473 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-06-30 0001695473 us-gaap:CommonStockMember 2025-06-30 0001695473 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001695473 us-gaap:RetainedEarningsMember 2025-06-30 0001695473 2025-06-30 0001695473 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-12-31 0001695473 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2025-12-31 0001695473 us-gaap:CommonStockMember 2025-12-31 0001695473 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001695473 us-gaap:RetainedEarningsMember 2025-12-31 0001695473 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2026-01-01 2026-03-31 0001695473 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2026-01-01 2026-03-31 0001695473 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001695473 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001695473 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001695473 2026-01-01 2026-03-31 0001695473 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2026-03-31 0001695473 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2026-03-31 0001695473 us-gaap:CommonStockMember 2026-03-31 0001695473 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001695473 us-gaap:RetainedEarningsMember 2026-03-31 0001695473 2026-03-31 0001695473 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2026-04-01 2026-06-30 0001695473 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2026-04-01 2026-06-30 0001695473 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0001695473 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0001695473 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0001695473 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2026-06-30 0001695473 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2026-06-30 0001695473 us-gaap:CommonStockMember 2026-06-30 0001695473 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001695473 us-gaap:RetainedEarningsMember 2026-06-30 0001695473 GCAN:GreenCCorporationMember GCAN:ClassACommonStockMember 2018-07-31 0001695473 GCAN:GreenCCorporationMember GCAN:SeriesAConvertiblePreferredStockMember 2018-07-31 2018-07-31 0001695473 GCAN:FormerShareHoldersMember GCAN:GreenCCorporationMember 2018-07-31 0001695473 GCAN:LicensingAgreementMember 2021-06-21 0001695473 srt:MinimumMember GCAN:LicensingAgreementMember 2021-06-21 2021-06-21 0001695473 srt:MaximumMember GCAN:LicensingAgreementMember 2021-06-21 2021-06-21 0001695473 GCAN:LicensingAgreementMember 2021-06-21 2021-06-21 0001695473 us-gaap:SeriesBPreferredStockMember 2025-10-16 2025-10-16 0001695473 2025-10-16 0001695473 GCAN:GreenCCorporationMember 2025-10-16 0001695473 GCAN:SeriesBConvertiblePreferredStockMember 2025-10-16 0001695473 us-gaap:SeriesBPreferredStockMember 2026-06-29 2026-06-29 0001695473 GCAN:CBDMember GCAN:KolTuvVenturesLLCMember GCAN:RightOfFirstRefusalAgreementMember 2020-01-30 2020-01-30 0001695473 GCAN:ElishaKalfaAndYonahKalfaMember 2026-06-30 0001695473 GCAN:ElishaKalfaAndYonahKalfaMember 2025-12-31 0001695473 GCAN:AitanZacharinMember 2026-06-30 0001695473 GCAN:AitanZacharinMember 2025-12-31 0001695473 GCAN:FernandoBiskerAndSigalushLLCMember 2026-06-30 0001695473 GCAN:FernandoBiskerAndSigalushLLCMember 2025-12-31 0001695473 GCAN:ElishaKalfaAndYonahKalfaMember GCAN:SeriesAConvertiblePreferredStockMember 2025-01-01 2025-12-31 0001695473 GCAN:ElishaKalfaAndYonahKalfaMember GCAN:SeriesAConvertiblePreferredStockMember 2026-01-01 2026-06-30 0001695473 GCAN:FernandoBiskerAndSigalushLLCMember GCAN:SeriesAConvertiblePreferredStockMember 2025-01-01 2025-12-31 0001695473 GCAN:FernandoBiskerAndSigalushLLCMember GCAN:SeriesAConvertiblePreferredStockMember 2026-01-01 2026-06-30 0001695473 srt:MaximumMember GCAN:LoanAndContributionAgreementsMember 2018-07-30 2018-07-31 0001695473 GCAN:PromissoryNoteMember 2026-06-30 0001695473 GCAN:PromissoryNoteMember 2025-12-31 0001695473 GCAN:ConvertiblePromissoryNoteMember 2026-06-30 0001695473 GCAN:ConvertiblePromissoryNoteMember 2025-12-31 0001695473 GCAN:PromissoryNoteMember GCAN:JohnT.RootMember 2017-03-28 0001695473 GCAN:PromissoryNoteMember GCAN:JohnT.RootMember 2017-03-28 2017-03-28 0001695473 GCAN:ConvertiblePromissoryNoteMember GCAN:FirstFireGlobalOpportunitiesFundLLCMember 2021-03-15 0001695473 GCAN:ConvertiblePromissoryNoteMember GCAN:FirstFireGlobalOpportunitiesFundLLCMember 2026-06-30 0001695473 GCAN:ConvertiblePromissoryNoteMember GCAN:FirstFireGlobalOpportunitiesFundLLCMember 2025-12-31 0001695473 GCAN:ConvertiblePromissoryNoteMember GCAN:FirstFireGlobalOpportunitiesFundLLCMember 2021-03-15 2021-03-15 0001695473 GCAN:ConvertiblePromissoryNoteMember GCAN:FirstFireGlobalOpportunitiesFundLLCMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-06-29 2021-06-30 0001695473 GCAN:ConvertiblePromissoryNoteMember GCAN:FirstFireGlobalOpportunitiesFundLLCMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-06-30 0001695473 GCAN:FirstFireNoteMember 2022-06-01 2022-06-01 0001695473 GCAN:FirstFireNoteMember 2022-06-01 0001695473 GCAN:FirstFireNoteMember 2022-07-01 2022-09-30 0001695473 GCAN:FirstFireNoteMember 2022-09-30 0001695473 GCAN:FirstFireNoteMember 2022-10-01 2022-12-31 0001695473 GCAN:FirstFireNoteMember 2022-12-31 0001695473 GCAN:FirstFireNoteOneMember 2025-01-01 2025-03-31 0001695473 GCAN:FirstFireNoteOneMember 2025-03-31 0001695473 GCAN:FirstFireNoteTwoMember 2025-01-01 2025-03-31 0001695473 GCAN:FirstFireNoteTwoMember 2025-03-31 0001695473 GCAN:FirstFireNoteMember 2025-04-01 2025-06-30 0001695473 srt:MinimumMember GCAN:FirstFireNoteMember 2025-06-30 0001695473 srt:MaximumMember GCAN:FirstFireNoteMember 2025-06-30 0001695473 2025-06-12 2025-06-12 0001695473 2025-10-01 2025-10-31 0001695473 GCAN:SecondFirstFireNoteMember 2021-04-01 2021-06-30 0001695473 GCAN:LessThanOrEqualsToThirtyDaysMember GCAN:FFNoteMember 2026-01-01 2026-06-30 0001695473 GCAN:ThirtyOneToSixtyDaysMember GCAN:FFNoteMember 2026-01-01 2026-06-30 0001695473 GCAN:SixtyOneToNinetyDaysMember GCAN:FFNoteMember 2026-01-01 2026-06-30 0001695473 GCAN:NinetyOneToHundredAndTwentyMember GCAN:FFNoteMember 2026-01-01 2026-06-30 0001695473 GCAN:OnehundredAndTwentyOneToOneHundredFiftyDaysMember GCAN:FFNoteMember 2026-01-01 2026-06-30 0001695473 GCAN:OneHundredAndFiftyOneToOneHundredAndEightyMember GCAN:FFNoteMember 2026-01-01 2026-06-30 0001695473 GCAN:ConvertiblePromissoryNoteMember GCAN:FirstFireGlobalOpportunitiesFundLLCMember 2021-06-29 2021-06-30 0001695473 GCAN:ConvertiblePromissoryNoteMember us-gaap:MeasurementInputSharePriceMember 2020-12-31 0001695473 GCAN:ConvertiblePromissoryNoteMember us-gaap:MeasurementInputConversionPriceMember 2020-12-31 0001695473 GCAN:ConvertiblePromissoryNoteMember us-gaap:MeasurementInputExpectedTermMember 2020-12-31 2020-12-31 0001695473 GCAN:ConvertiblePromissoryNoteMember us-gaap:MeasurementInputPriceVolatilityMember 2020-12-31 0001695473 GCAN:ConvertiblePromissoryNoteMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-12-31 0001695473 GCAN:ConvertiblePromissoryNoteMember us-gaap:MeasurementInputSharePriceMember 2021-06-30 0001695473 GCAN:ConvertiblePromissoryNoteMember us-gaap:MeasurementInputConversionPriceMember 2021-06-30 0001695473 GCAN:ConvertiblePromissoryNoteMember us-gaap:MeasurementInputExpectedTermMember 2021-06-30 2021-06-30 0001695473 GCAN:ConvertiblePromissoryNoteMember us-gaap:MeasurementInputPriceVolatilityMember 2021-06-30 0001695473 GCAN:ConvertiblePromissoryNoteMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-06-30 0001695473 GCAN:GreenCCorporationMember us-gaap:CommonClassAMember 2018-07-31 0001695473 GCAN:SeriesBConvertiblePreferredStockMember GCAN:EmetCapitalPartnersLLCMember 2019-02-14 2019-02-14 0001695473 GCAN:SeriesBConvertiblePreferredStockMember GCAN:EmetCapitalPartnersLLCMember 2019-02-14 0001695473 us-gaap:SeriesAPreferredStockMember 2021-09-21 2021-09-21 0001695473 us-gaap:CommonStockMember 2021-09-21 2021-09-21 0001695473 GCAN:SeriesBConvertiblePreferredStockMember 2025-10-22 0001695473 GCAN:AitanZacharinMember GCAN:SeriesBConvertiblePreferredStockMember 2025-10-22 0001695473 srt:ChiefExecutiveOfficerMember GCAN:SeriesBConvertiblePreferredStockMember 2025-10-22 2025-10-22 0001695473 2025-10-22 0001695473 GCAN:SeriesBConvertiblePreferredStockMember 2025-10-22 2025-10-22 0001695473 2017-03-10 2017-03-10 0001695473 GCAN:SyliosCorpMember 2017-03-10 2017-03-10 0001695473 GCAN:SyliosCorpMember 2017-03-10 0001695473 GCAN:SyliosCorpMember 2017-02-03 2017-02-03 0001695473 GCAN:SyliosCorpMember 2017-02-03 0001695473 GCAN:EmetCapitalPartnersLLCMember 2019-01-04 2019-01-04 0001695473 GCAN:EmetCapitalPartnersLLCMember 2019-01-04 0001695473 GCAN:EmetCapitalPartnersLLCMember 2019-01-01 2019-03-31 0001695473 GCAN:EmetCapitalPartnersLLCMember 2017-05-25 2017-05-25 0001695473 GCAN:EmetCapitalPartnersLLCMember 2019-04-16 2019-04-16 0001695473 GCAN:EmetCapitalPartnersLLCMember 2019-04-16 0001695473 GCAN:EmetCapitalPartnersLLCMember 2019-04-01 2019-06-30 0001695473 GCAN:TwoConsultingFirmEntitiesMember 2019-05-29 2019-05-29 0001695473 2019-04-01 2019-06-30 0001695473 2019-08-15 2019-08-15 0001695473 GCAN:EmetCapitalPartnersLLCMember GCAN:TwoExchangeAgreementMember 2019-10-18 0001695473 GCAN:EmetCapitalPartnersLLCMember GCAN:TwoExchangeAgreementMember 2019-10-18 2019-10-18 0001695473 GCAN:EmetCapitalPartnersLLCMember GCAN:SecondExchangeAgreementMember 2019-02-14 2019-02-14 0001695473 GCAN:EmetCapitalPartnersLLCMember GCAN:SecondExchangeAgreementMember 2019-02-14 0001695473 2019-11-11 2019-11-11 0001695473 2019-11-11 0001695473 2019-12-20 2019-12-20 0001695473 2019-12-20 0001695473 2019-12-24 2019-12-24 0001695473 2019-12-24 0001695473 GCAN:ConvertibleNotesMember 2020-01-01 2020-03-31 0001695473 GCAN:ConvertibleNotesMember 2020-03-31 0001695473 2020-01-01 2020-03-31 0001695473 2020-03-31 0001695473 GCAN:ConvertibleNotesMember 2020-04-01 2020-06-30 0001695473 GCAN:ConvertibleNotesMember 2020-06-30 0001695473 2020-04-01 2020-06-30 0001695473 2020-06-30 0001695473 GCAN:ConvertibleNotesMember 2020-07-01 2020-09-30 0001695473 GCAN:ConvertibleNotesMember 2020-09-30 0001695473 2020-07-01 2020-09-30 0001695473 2020-09-30 0001695473 GCAN:ConvertibleNotesMember 2020-10-01 2020-12-31 0001695473 GCAN:ConvertibleNotesMember 2020-12-31 0001695473 2020-10-01 2020-12-31 0001695473 2020-12-31 0001695473 GCAN:NotesPayableMember 2021-06-30 0001695473 GCAN:NotesPayableMember 2021-01-01 2021-06-30 0001695473 GCAN:FirstFireNoteMember 2021-07-15 2021-07-15 0001695473 GCAN:FirstFireNoteMember 2021-07-15 0001695473 GCAN:FirstFireNoteMember 2023-01-01 2023-12-31 0001695473 GCAN:FirstFireNoteMember 2023-12-31 0001695473 2025-02-16 2025-02-17 0001695473 2025-04-03 2025-04-03 0001695473 2025-04-03 0001695473 us-gaap:CommonStockMember 2025-10-15 2025-10-15 0001695473 srt:MaximumMember us-gaap:CommonStockMember 2025-10-15 2025-10-15 0001695473 srt:MinimumMember us-gaap:CommonStockMember 2025-10-15 2025-10-15 0001695473 GCAN:FirstFireNoteMember 2025-10-22 2025-10-22 0001695473 GCAN:FirstFireNoteMember 2025-10-22 0001695473 GCAN:WarrantAMember GCAN:FirstFireGlobalOpportunitiesFundLLCMember 2021-03-11 0001695473 GCAN:WarrantBMember GCAN:FirstFireGlobalOpportunitiesFundLLCMember 2021-03-11 0001695473 GCAN:WarrantCMember GCAN:FirstFireGlobalOpportunitiesFundLLCMember 2021-03-11 0001695473 GCAN:WarrantAMember GCAN:FirstFireGlobalOpportunitiesFundLLCMember 2021-06-30 0001695473 GCAN:GreenCCorporationMember GCAN:ExclusiveLicenseAgreementMember 2018-06-21 2018-06-21 0001695473 GCAN:PharmedicaLtdMember 2019-01-01 2019-12-31 0001695473 GCAN:PharmedicaLtdMember 2019-12-31 0001695473 GCAN:GreenCCorporationMember GCAN:ExclusiveLicenseAgreementMember 2020-07-01 2020-09-30 0001695473 GCAN:GreenCCorporationMember GCAN:ExclusiveLicenseAgreementMember 2020-09-30 0001695473 srt:MinimumMember GCAN:SubLicenseAgreementMember GCAN:SymtomaxUnipessoalLdaMember 2019-07-15 2019-07-15 0001695473 srt:MaximumMember GCAN:SubLicenseAgreementMember GCAN:SymtomaxUnipessoalLdaMember 2019-07-15 2019-07-15 0001695473 srt:MaximumMember GCAN:SubLicenseAgreementMember GCAN:SymtomaxUnipessoalLdaMember 2020-05-27 2020-05-27 0001695473 srt:ChiefExecutiveOfficerMember GCAN:ServicesAgreementsMember 2018-07-31 2018-07-31 0001695473 GCAN:ServicesAgreementsMember 2026-01-01 2026-06-30 0001695473 GCAN:ServicesAgreementsMember 2025-01-01 2025-06-30 iso4217:USD shares iso4217:USD shares pure utr:D false Q2 --12-31 0001695473

10-Q true 2026-06-30 2026 false 000-56027 TRAFALGAR INTERNATIONAL, INC. FL 30-0842570 200 South Biscayne Blvd Fl 20 Miami FL 33131 +52 1 55 6449 4966 Yes Yes Non-accelerated Filer true false false 994379

111

815

111

815

25000

111

815

12239

8514

470350

263600

12239

742464

19000000

0.001

7628655

9111998

7629

9112

1000

0.001

1000

true true

2000000000

0.001

994379

944935

1349983

1349933

3044214

2891262

-4413955

-4991957

-12128

-741649

111

815

30000

11555

18251

11555

48251

-11555

-48251

621450 1483

885

167417

-174300

622933

-342602

611378

-390853

611378

-390853

0.61

-0.43

994379

919141

30000

60000

1800

417

14931

29570

44931

91787

-44931

-91787

621450 1483

2940

306323

-232220

622933

-541483

578002

-633270

578002

-633270

0.60

-0.81

969657

784704

9111998

9112

804638436

804639

3006321

-4660345

-840273

168000000

168000

-50000

118000

2250000

2250

-450

1800

2250

-450

1800

2250

-450

1800

2250

-450

1800

2250

-450

1800

-242417

9111998

9112

974888436

974889

2955871

-4902762

-962890

275000000

275000

-3500

271500

275000000

275000

-3500

271500

100000000

100000

-90000

10000

100000000

100000

-90000

10000

-390853

9111998

9112

1349888436

1349889

2862371

-5293615

-1072243

9111998

9112

1000

944935

1349933

2891262

-4991957

-741649

-33376

9111998

9112

1000

944935

1349933

2891262

-5025333

-775025

-9111998

9112

7628655

7629

49444

152952

153002

49444

152952

153002

611378

7628655

7629

1000

994379

1349983

3044214

-4413955

-12128

578002

-633270

417

1800

153002 10000

-232220

306323 621450 1483

3725

-1086

2940

-123000

50000

-11204

-30656

10500

-704

-30656

815

57368

111

26712

NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Nature of Operations Trafalgar International, Inc., f/k/a The Greater Cannabis Company, Inc. (the “Company”) was formed in March 2014 as a limited liability company under the name, The Greater Cannabis Company, LLC. The Company was a wholly owned subsidiary of Sylios Corp (“Sylios”) until March 10, 2017. On July 31, 2018, the Company acquired <span id="xdx_90A_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20180731__us-gaap--BusinessAcquisitionAxis__custom--GreenCCorporationMember__us-gaap--StatementClassOfStockAxis__custom--ClassACommonStockMember_zUyy6FG8X1Ee" title="Percentage of issued and outstanding shares acquired">100% of the issued and outstanding shares of Class A common stock of Green C Corporation (“Green C”) in exchange for <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20180731__20180731__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--BusinessAcquisitionAxis__custom--GreenCCorporationMember_zKrypFrGpNM4" title="Number of shares issued">9,411,998 newly issued shares of the Company’s Series A Convertible Preferred Stock (the “Exchange”). <span id="xdx_904_eus-gaap--CommonStockVotingRights_c20180731__20180731__us-gaap--BusinessAcquisitionAxis__custom--GreenCCorporationMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zqZJrto76Yv7" title="Common stock, voting rights">Each share of Series A Convertible Preferred Stock is convertible into 50 shares of common stock and is entitled to vote 50 votes per share on all matters as a class with holders of common stock. Since after the Exchange was consummated, the former shareholders of Green C and their designees owned approximately <span id="xdx_901_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20180731__srt--TitleOfIndividualAxis__custom--FormerShareHoldersMember__us-gaap--BusinessAcquisitionAxis__custom--GreenCCorporationMember_zL1gkiumPocd" title="Percentage of issued and outstanding shares acquired">94% of the issued and outstanding voting shares of the Company, Green C is the acquirer for accounting purposes. Prior to the Exchange, the Company had no assets and nominal business operations. Accordingly, the Exchange has been treated for accounting purposes as a recapitalization by the accounting acquirer, Green C, and the accompanying consolidated financial statements of the Company reflect the assets, liabilities and operations of Green C from its inception on December 21, 2017 to July 31, 2018 and combined with the Company thereafter. Green C was incorporated on December 21, 2017 under the laws of the Province of Ontario Canada with its principal place of business in North York, Ontario. Green C was the owner of an exclusive, worldwide license for an eluting transmucosal patch platform (“ETP”) for non-invasive drug delivery in the cannabis field as further described in the exclusive license agreement dated June 21, 2018 with Pharmedica Ltd. (see Note J). After the consummation of the above-described transactions, the Company switched its business model in fiscal 2018 and no longer intended to pursue E-commerce, advertising, licensing (except as specified below) or direct investment operations to the development and commercialization of innovative cannabinoid therapeutic delivery systems. From July 2018 through mid-2021, the Company focused on commercializing its own and licensed technologies worldwide for transmucosal and transdermal delivery of legal medical or recreational cannabis (other than in the field of oral care) and cannabinoids. The Company’s initial product was an oral transmucosal patch platform which for provides for loaded actives to be absorbed by the buccal mucosa into the body. Although the Company was able to launch the product and received some limited initial orders, the Company’s management ultimately elected to pursue other opportunities which they believed offered the Company greater potential for growth and ultimate profitability. Accordingly, on October 19, 2021 the Company entered into a license agreement with Shaare Zedek Scientific Ltd. (“SZS”), the technology transfer arm of Jerusalem’s Shaare Zedek Medical Center (SZMC). The license agreement covers the license of SZS’s novel cannabinoid therapeutic focused on treatment of autism, schizophrenia, Parkinson’s disease, Alzheimer’s disease and other neuropsychiatric disorders. Accompanying the license agreement is a joint research and development agreement, which will focus on continuing the clinical program spearheaded by Dr. Adi Aran, M.D. Director of Pediatric Neurology at SZMC, Board Member of the Israeli Society for Pediatric Neurology, and co-inventor of the novel cannabinoid therapy. TRAFALGAR INTERNATIONAL, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Six Months Ended June 30, 2026 and 2025 (Unaudited) NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) The licensing agreement requires the Company to pay $5,000 per year beginning on the third year from the Effective Date, which was June 21, 2021. The licensing fee is increased every two calendar years by an additional $<span id="xdx_90C_ecustom--IncreaseDecreaseInLicensingFee_c20210621__20210621__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMember__srt--RangeAxis__srt--MinimumMember_zQFdOg2DW5M2" title="Licensing fee">5,000 up to a maximum of $<span id="xdx_906_ecustom--IncreaseDecreaseInLicensingFee_c20210621__20210621__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMember__srt--RangeAxis__srt--MaximumMember_zOijmPTlN19l" title="Increase in licensing fee">30,000. Additionally, there are milestone payments of $75,000 upon initiation of the Phase 2 Clinical Trial, $<span id="xdx_904_ecustom--MilestonePaymentsOnInitiationOfClinicalTrial_c20210621__20210621__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMember_zOqSg3oY5Yk9" title="Milestone payments on initiation of clinical trial">200,000 from the initiation of a Phase 3 Clinical Trial, and $<span id="xdx_904_ecustom--MilestonePaymentsOnFirstRegulatoryApproval_c20210621__20210621__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMember_zBrjYMrIcrO5" title="Milestone payments on first regulatory approval">300,000 upon receipt of the first regulatory approval for a drug product. The licensing fees are due 30 days from the beginning of each calendar year. The developmental milestone payments are due 60 days from the date that the milestone has been achieved. At this time the Company is waiting for the Principal Investigator (PI) to source the specialized active pharmaceutical ingredients (API) required to facilitate the Phase 2 Clinical Trial, and as such the annual licensing fee payments have been put on hold. It is not known when the specialized and proprietary API will be able to be sourced. The royalties for dietary supplement sales are 2.25% for net sales between $1-$10 million, 2.5% for net sales between $10 million and $50 million, and 3% for net sales between $50 million and $100 million. Royalty payments for dietary products are capped at $100 million in net sales. Royalties for drug products are 1% for net sales between $1 and $100 million, 1.5% for net sales between $100 million and $500 million, and 2% for net sales greater than $500 million. There is a sublicense royalty of 12%. The Company has concluded the preclinical studies as was communicated in a press release issued by the Company on February 27, 2024. The Company received approval from the Israel Ministry of Health to proceed with a Phase II Clinical Trial as communicated by the Company in a press release on July 5, 2023. The Company is now waiting for the PI to source the API needed for the clinical trial. In order to proceed with the Clinical Trial the Company will need to raise additional funds to finance the cost of the Phase II Clinical Trial. The Clinical Trial is expected to take between 18 and 24 months from the start date to complete. The regulatory approval timeline is uncertain at this time as the Company is awaiting clinical data from the Phase II Clinical Trial in order to submit an application to the FDA to begin the regulatory process. Reverse Stock Split and Series B Preferred Shares: The Company filed an amendment to its Certificate of Incorporation with the Secretary of State of Florida to effectuate a 1-for-1,500 reverse stock split of its Common Stock (the “Reverse Split”) effective October 16, 2025. Share, equity award, and per share amounts contained in the consolidated financial statements have been adjusted to reflect the Reverse Stock Splits for all prior periods presented. (See Note-J) This Information Statement (the “Information Statement”) has been filed with the Securities and Exchange Commission and is being furnished, pursuant to Section 14C of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), to the holders of common stock, par value $.001 per share (the “Common Stock”), of The Greater Cannabis Company, Inc., a Florida corporation (the “Company”), to notify shareholders that on or about April 4, 2025, the Company received written consents in lieu of a meeting from (a) the sole director of the Company; and (b) holders of shares of voting stock of the Company representing approximately <span id="xdx_902_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20251016__us-gaap--BusinessAcquisitionAxis__custom--GreenCCorporationMember_ziVIeheIVez8" title="Percentage of issued and outstanding shares acquired">50.3% of total voting power of the issued and outstanding shares of voting stock of the Company (the “Majority Shareholders”), authorizing the Company to amend its Articles of Incorporation to: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">to effectuate a reverse stock split of the Company’s issued outstanding shares of common stock in a ratio of one-for-1,500; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">create a new class of 1,000 shares of preferred stock, $<span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20251016__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zSK6aX6evz89" title="Preferred stock, par value">.001 per share, designated as Series B Convertible Preferred Stock</td></tr> </table> The reverse stock split became effective upon the filing of an amendment to the Company’s Articles of Incorporation with the Florida Secretary of State, a copy of which is included as Exhibit 33.1 in this Quarterly Report (the “Reverse Stock Split Amendment”). The amendment creating the Series B Preferred Shares was subsequently filed with the Florida Secretary of State following the filing of the Reverse Stock Split Amendment. On June 29, 2026, the Controlling Shareholder entered into the Share Purchase. Through the Controlling Shareholder’s ownership of all outstanding shares of the Company’s Series A Preferred Stock and Series B Preferred Stock, Trafalgar Asset Management, LLC possesses approximately 96.62% of the aggregate voting power of the Company’s outstanding voting securities as of June 29, 2026, based upon 994,379 shares of Common Stock outstanding, each share of Series A Preferred Stock being entitled to 1.76 votes per share, and the outstanding shares of Series B Preferred Stock collectively being entitled to 51% of all votes entitled to be cast. As a result, the Controlling Shareholder possesses voting control of the Company and may unilaterally determine the election of directors and substantially all matters requiring stockholder approval. The acquisition of control was effected pursuant to privately negotiated transactions contemplated by the Series A Share Purchase Agreement and the Series B Share Purchase Agreement, copies of which are filed as Exhibits 10.1 and 10.2 to this Current Report and incorporated herein by reference. The material terms of such transactions, including the consideration paid thereunder, are set forth in such agreements. Also on June 29, 2026, the Company entered into certain Debt Cancellation and Release Agreements with certain creditors of the Company pursuant to which certain outstanding indebtedness of the Company was compromised, settled, canceled, released, and extinguished. Copies of such Debt Cancellation and Release Agreements are filed as Exhibits 10.3 and 10.4 to this Current Report and incorporated herein by reference. The material terms of such transactions are set forth in such agreements. Porfirio Sanchez Talavera was appointed as Chief Executive Officer, Chairman of the Board, and a member of the Board of Directors of the Company. Aitan Zacharin resigned from all officer positions effective immediately upon such appointment and agreed to remain as a member of the Board of Directors solely until the expiration of the ten (10) day period required under Rule 14f-1. Upon expiration of such period, Mr. Zacharin’s resignation as a director will become effective and Mr. Sanchez Talavera will remain as the sole director of the Company. Principles of Consolidation The consolidated financial statements include the accounts of Trafalgar International, Inc., and its wholly owned subsidiary Biocanrx, Inc. All intercompany balances and transactions have been eliminated in consolidation. TRAFALGAR INTERNATIONAL, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Six Months Ended June 30, 2026 and 2025 (Unaudited) NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) Interim Financial Statements The interim financial statements as of June 30, 2026 are unaudited and have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission. These statements reflect all normal and recurring adjustments that, in the opinion of management, are necessary for a fair presentation of the information contained herein. Operating results for the six months ended June 30, 2026 are not necessarily indicative of results that may be expected for the year ending December 31, 2026. Certain information and finance disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to the Securities and Exchange Commission’s rules and regulations. These unaudited financial statements should be read in conjunction with our audited financial statements and notes for the year ended December 31, 2025 as included in our report on Form 10-K. Cash and Cash Equivalents Investments having an original maturity of 90 days or less that are readily convertible into cash are considered to be cash equivalents. For the periods presented, the Company had no cash equivalents. Notes and Accounts Receivable The Company maintains an allowance for doubtful accounts for estimated losses from the failure of its customers to make required payments for products and other consideration delivered. The Company estimates this allowance based on the age of the related receivable, knowledge of the financial condition of customers, review of historical receivables and reserve trends and other pertinent information. If the financial condition of customers deteriorates or an unfavorable trend in receivable collections is experienced in the future, additional allowances may be required. Historically, the Company’s reserves have approximated actual experience. Income Taxes In accordance with Accounting Standards Codification (ASC) 740 - Income Taxes, the provision for income taxes is computed using the asset and liability method. The asset and liability method measures deferred income taxes by applying enacted statutory rates in effect at the balance sheet date to the differences between the tax basis of assets and liabilities and their reported amounts on the financial statements. The resulting deferred tax assets or liabilities are adjusted to reflect changes in tax laws as they occur. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized. We expect to recognize the financial statement benefit of an uncertain tax position only after considering the probability that a tax authority would sustain the position in an examination. For tax positions meeting a “more-likely-than-not” threshold, the amount to be recognized in the financial statements will be the benefit expected to be realized upon settlement with the tax authority. For tax positions not meeting the threshold, no financial statement benefit is recognized. As of June 30, 2026, we had no uncertain tax positions. We recognize interest and penalties, if any, related to uncertain tax positions as general and administrative expenses. We currently have no foreign federal or state tax examinations nor have we had any foreign federal or state examinations since our inception. To date, we have not incurred any interest or tax penalties. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates. Financial Instruments and Fair Value of Financial Instruments We follow ASC Topic 820, Fair Value Measurements and Disclosures, for assets and liabilities measured at fair value on a recurring basis. ASC Topic 820 establishes a common definition for fair value to be applied to existing US GAAP that requires the use of fair value measurements that establishes a framework for measuring fair value and expands disclosure about such fair value measurements. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC Topic 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below: TRAFALGAR INTERNATIONAL, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Six Months Ended June 30, 2026 and 2025 (Unaudited) NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">Level 1:</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Observable inputs such as quoted market prices in active markets for identical assets or liabilities</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2:</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Observable market-based inputs or unobservable inputs that are corroborated by market data</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3:</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions.</td></tr> </table> The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. Except for derivative liabilities, we had no financial assets or liabilities carried and measured on a recurring or nonrecurring basis during the reporting periods. Derivative Liabilities We evaluate convertible notes payable, stock options, stock warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under the relevant sections of ASC Topic 815-40, Derivative Instruments and Hedging: Contracts in Entity’s Own Equity. The result of this accounting treatment could be that the fair value of a financial instrument is classified as a derivative instrument and is marked-to-market at each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income or other expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Financial instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815-40 are reclassified to a liability account at the fair value of the instrument on the reclassification date. Long-lived Assets Long-lived assets such as property and equipment and intangible assets are periodically reviewed for impairment. We test for impairment losses on long-lived assets used in operations whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. Impairment evaluations involve management’s estimates on asset useful lives and future cash flows. Actual useful lives and cash flows could be different from those estimated by management which could have a material effect on our reporting results and financial positions. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. TRAFALGAR INTERNATIONAL, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Six Months Ended June 30, 2026 and 2025 (Unaudited) NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) Equity Instruments Issued to Non-Employees for Acquiring Goods or Services Issuances of our common stock or warrants for acquiring goods or services are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The measurement date for the fair value of the equity instruments issued to consultants or vendors is determined at the earlier of (i) the date at which a commitment for performance to earn the equity instruments is reached (a “performance commitment” which would include a penalty considered to be of a magnitude that is a sufficiently large disincentive for nonperformance) or (ii) the date at which performance is complete. Although situations may arise in which counter performance may be required over a period of time, the equity award granted to the party performing the service may be fully vested and non-forfeitable on the date of the agreement. As a result, in this situation in which vesting periods do not exist if the instruments are fully vested on the date of agreement, we determine such date to be the measurement date and will record the estimated fair market value of the instruments granted as a prepaid expense and amortize such amount to expense over the contract period. When it is appropriate for us to recognize the cost of a transaction during financial reporting periods prior to the measurement date, for purposes of recognition of costs during those periods, the equity instrument is measured at the then-current fair values. Related Parties A party is considered to be related to us if the party directly or indirectly or through one or more intermediaries, controls, is controlled by, or is under common control with us. Related parties also include our principal owners, our management, members of the immediate families of our principal owners and our management and other parties with which we may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. A party which can significantly influence the management or operating policies of the transacting parties, or if it has an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests, is also a related party. TRAFALGAR INTERNATIONAL, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Six Months Ended June 30, 2026 and 2025 (Unaudited) NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) Revenue Recognition Revenue recognition: The Company adopted Accounting Standards Codification Topic 606, “Revenue from Contracts with Customers” (“ASC 606”) on January 1, 2018. In accordance with ASC 606, revenue is recognized when promised goods or services are transferred to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services, in accordance with the following five-step process: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif">Identify the contract(s) with a customer</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">●</td> <td style="font: 10pt Times New Roman, Times, Serif">Identify the performance obligations</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">●</td> <td style="font: 10pt Times New Roman, Times, Serif">Determine the transaction price</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">●</td> <td style="font: 10pt Times New Roman, Times, Serif">Allocate the transaction price</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">●</td> <td style="font: 10pt Times New Roman, Times, Serif">Recognize revenue when the performance obligations are met</td></tr> </table> The Company recognizes revenue from the sale of products when its performance obligation, consisting of the delivery of the purchased goods to the customer, has been satisfied and the customer takes possession. The Company had no revenue during the periods presented. Advertising Costs Advertising costs are expensed as incurred. For the periods presented, we had no advertising costs. Loss per Share We compute net income (loss) per share in accordance with FASB ASC 260, Earnings Per Share, which specifies the computation, presentation and disclosure requirements for earnings per share for entities with publicly held common stock. Basic net income (loss) per common share is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per common share is computed using the weighted average number of common shares outstanding during the period, adjusted for the effect of potentially dilutive securities, including convertible preferred stock, stock options, warrants and other convertible securities, when their inclusion would be dilutive. Potential common shares are excluded from the calculation of diluted net income (loss) per common share when their effect would be anti-dilutive. For the periods presented, shares issuable upon conversion of the Company’s Series A Convertible Preferred Stock were excluded from the calculation of diluted net income (loss) per common share because the effect of their inclusion would be anti-dilutive. As of June 30, 2026, the Company had no outstanding convertible notes payable to third parties (see Note E – Notes Payable to Third Parties) and no outstanding warrants (see Note G – Capital Stock and Warrants). TRAFALGAR INTERNATIONAL, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Six Months Ended June 30, 2026 and 2025 (Unaudited) NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) Recently Enacted Accounting Standards In August 2020, the FASB issued ASU 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40)”. This ASU reduces the number of accounting models for convertible debt instruments and convertible preferred stock. As well as amend the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. In addition, this ASU improves and amends the related EPS guidance. This standard is effective for us on July 1, 2024, including interim periods within those fiscal years. Adoption is either a modified retrospective method or a fully retrospective method of transition. We are currently evaluating the impact of the adoption of ASU 2020-06 on our financial statements. In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-13, “Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”). Financial Instruments—Credit Losses (Topic 326) amends guideline on reporting credit losses for assets held at amortized cost basis and available-for-sale debt securities. For assets held at amortized cost basis, Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current estimate of all expected credit losses. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. For available-for-sale debt securities, credit losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance rather than as a write-down. ASU 2016-13 affects entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. The amendments in this ASU will be effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. We are currently evaluating the impact of the adoption of ASU 2016-13 on our financial statements. Other standards not presented are not deemed to be material. TRAFALGAR INTERNATIONAL, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Six Months Ended June 30, 2026 and 2025 (Unaudited)

Nature of Operations Trafalgar International, Inc., f/k/a The Greater Cannabis Company, Inc. (the “Company”) was formed in March 2014 as a limited liability company under the name, The Greater Cannabis Company, LLC. The Company was a wholly owned subsidiary of Sylios Corp (“Sylios”) until March 10, 2017. On July 31, 2018, the Company acquired <span id="xdx_90A_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20180731__us-gaap--BusinessAcquisitionAxis__custom--GreenCCorporationMember__us-gaap--StatementClassOfStockAxis__custom--ClassACommonStockMember_zUyy6FG8X1Ee" title="Percentage of issued and outstanding shares acquired">100% of the issued and outstanding shares of Class A common stock of Green C Corporation (“Green C”) in exchange for <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20180731__20180731__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--BusinessAcquisitionAxis__custom--GreenCCorporationMember_zKrypFrGpNM4" title="Number of shares issued">9,411,998 newly issued shares of the Company’s Series A Convertible Preferred Stock (the “Exchange”). <span id="xdx_904_eus-gaap--CommonStockVotingRights_c20180731__20180731__us-gaap--BusinessAcquisitionAxis__custom--GreenCCorporationMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zqZJrto76Yv7" title="Common stock, voting rights">Each share of Series A Convertible Preferred Stock is convertible into 50 shares of common stock and is entitled to vote 50 votes per share on all matters as a class with holders of common stock. Since after the Exchange was consummated, the former shareholders of Green C and their designees owned approximately <span id="xdx_901_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20180731__srt--TitleOfIndividualAxis__custom--FormerShareHoldersMember__us-gaap--BusinessAcquisitionAxis__custom--GreenCCorporationMember_zL1gkiumPocd" title="Percentage of issued and outstanding shares acquired">94% of the issued and outstanding voting shares of the Company, Green C is the acquirer for accounting purposes. Prior to the Exchange, the Company had no assets and nominal business operations. Accordingly, the Exchange has been treated for accounting purposes as a recapitalization by the accounting acquirer, Green C, and the accompanying consolidated financial statements of the Company reflect the assets, liabilities and operations of Green C from its inception on December 21, 2017 to July 31, 2018 and combined with the Company thereafter. Green C was incorporated on December 21, 2017 under the laws of the Province of Ontario Canada with its principal place of business in North York, Ontario. Green C was the owner of an exclusive, worldwide license for an eluting transmucosal patch platform (“ETP”) for non-invasive drug delivery in the cannabis field as further described in the exclusive license agreement dated June 21, 2018 with Pharmedica Ltd. (see Note J). After the consummation of the above-described transactions, the Company switched its business model in fiscal 2018 and no longer intended to pursue E-commerce, advertising, licensing (except as specified below) or direct investment operations to the development and commercialization of innovative cannabinoid therapeutic delivery systems. From July 2018 through mid-2021, the Company focused on commercializing its own and licensed technologies worldwide for transmucosal and transdermal delivery of legal medical or recreational cannabis (other than in the field of oral care) and cannabinoids. The Company’s initial product was an oral transmucosal patch platform which for provides for loaded actives to be absorbed by the buccal mucosa into the body. Although the Company was able to launch the product and received some limited initial orders, the Company’s management ultimately elected to pursue other opportunities which they believed offered the Company greater potential for growth and ultimate profitability. Accordingly, on October 19, 2021 the Company entered into a license agreement with Shaare Zedek Scientific Ltd. (“SZS”), the technology transfer arm of Jerusalem’s Shaare Zedek Medical Center (SZMC). The license agreement covers the license of SZS’s novel cannabinoid therapeutic focused on treatment of autism, schizophrenia, Parkinson’s disease, Alzheimer’s disease and other neuropsychiatric disorders. Accompanying the license agreement is a joint research and development agreement, which will focus on continuing the clinical program spearheaded by Dr. Adi Aran, M.D. Director of Pediatric Neurology at SZMC, Board Member of the Israeli Society for Pediatric Neurology, and co-inventor of the novel cannabinoid therapy. TRAFALGAR INTERNATIONAL, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Six Months Ended June 30, 2026 and 2025 (Unaudited) NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) The licensing agreement requires the Company to pay $5,000 per year beginning on the third year from the Effective Date, which was June 21, 2021. The licensing fee is increased every two calendar years by an additional $<span id="xdx_90C_ecustom--IncreaseDecreaseInLicensingFee_c20210621__20210621__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMember__srt--RangeAxis__srt--MinimumMember_zQFdOg2DW5M2" title="Licensing fee">5,000 up to a maximum of $<span id="xdx_906_ecustom--IncreaseDecreaseInLicensingFee_c20210621__20210621__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMember__srt--RangeAxis__srt--MaximumMember_zOijmPTlN19l" title="Increase in licensing fee">30,000. Additionally, there are milestone payments of $75,000 upon initiation of the Phase 2 Clinical Trial, $<span id="xdx_904_ecustom--MilestonePaymentsOnInitiationOfClinicalTrial_c20210621__20210621__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMember_zOqSg3oY5Yk9" title="Milestone payments on initiation of clinical trial">200,000 from the initiation of a Phase 3 Clinical Trial, and $<span id="xdx_904_ecustom--MilestonePaymentsOnFirstRegulatoryApproval_c20210621__20210621__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMember_zBrjYMrIcrO5" title="Milestone payments on first regulatory approval">300,000 upon receipt of the first regulatory approval for a drug product. The licensing fees are due 30 days from the beginning of each calendar year. The developmental milestone payments are due 60 days from the date that the milestone has been achieved. At this time the Company is waiting for the Principal Investigator (PI) to source the specialized active pharmaceutical ingredients (API) required to facilitate the Phase 2 Clinical Trial, and as such the annual licensing fee payments have been put on hold. It is not known when the specialized and proprietary API will be able to be sourced. The royalties for dietary supplement sales are 2.25% for net sales between $1-$10 million, 2.5% for net sales between $10 million and $50 million, and 3% for net sales between $50 million and $100 million. Royalty payments for dietary products are capped at $100 million in net sales. Royalties for drug products are 1% for net sales between $1 and $100 million, 1.5% for net sales between $100 million and $500 million, and 2% for net sales greater than $500 million. There is a sublicense royalty of 12%. The Company has concluded the preclinical studies as was communicated in a press release issued by the Company on February 27, 2024. The Company received approval from the Israel Ministry of Health to proceed with a Phase II Clinical Trial as communicated by the Company in a press release on July 5, 2023. The Company is now waiting for the PI to source the API needed for the clinical trial. In order to proceed with the Clinical Trial the Company will need to raise additional funds to finance the cost of the Phase II Clinical Trial. The Clinical Trial is expected to take between 18 and 24 months from the start date to complete. The regulatory approval timeline is uncertain at this time as the Company is awaiting clinical data from the Phase II Clinical Trial in order to submit an application to the FDA to begin the regulatory process. Reverse Stock Split and Series B Preferred Shares: The Company filed an amendment to its Certificate of Incorporation with the Secretary of State of Florida to effectuate a 1-for-1,500 reverse stock split of its Common Stock (the “Reverse Split”) effective October 16, 2025. Share, equity award, and per share amounts contained in the consolidated financial statements have been adjusted to reflect the Reverse Stock Splits for all prior periods presented. (See Note-J) This Information Statement (the “Information Statement”) has been filed with the Securities and Exchange Commission and is being furnished, pursuant to Section 14C of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), to the holders of common stock, par value $.001 per share (the “Common Stock”), of The Greater Cannabis Company, Inc., a Florida corporation (the “Company”), to notify shareholders that on or about April 4, 2025, the Company received written consents in lieu of a meeting from (a) the sole director of the Company; and (b) holders of shares of voting stock of the Company representing approximately <span id="xdx_902_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20251016__us-gaap--BusinessAcquisitionAxis__custom--GreenCCorporationMember_ziVIeheIVez8" title="Percentage of issued and outstanding shares acquired">50.3% of total voting power of the issued and outstanding shares of voting stock of the Company (the “Majority Shareholders”), authorizing the Company to amend its Articles of Incorporation to: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">to effectuate a reverse stock split of the Company’s issued outstanding shares of common stock in a ratio of one-for-1,500; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">create a new class of 1,000 shares of preferred stock, $<span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20251016__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zSK6aX6evz89" title="Preferred stock, par value">.001 per share, designated as Series B Convertible Preferred Stock</td></tr> </table> The reverse stock split became effective upon the filing of an amendment to the Company’s Articles of Incorporation with the Florida Secretary of State, a copy of which is included as Exhibit 33.1 in this Quarterly Report (the “Reverse Stock Split Amendment”). The amendment creating the Series B Preferred Shares was subsequently filed with the Florida Secretary of State following the filing of the Reverse Stock Split Amendment. On June 29, 2026, the Controlling Shareholder entered into the Share Purchase. Through the Controlling Shareholder’s ownership of all outstanding shares of the Company’s Series A Preferred Stock and Series B Preferred Stock, Trafalgar Asset Management, LLC possesses approximately 96.62% of the aggregate voting power of the Company’s outstanding voting securities as of June 29, 2026, based upon 994,379 shares of Common Stock outstanding, each share of Series A Preferred Stock being entitled to 1.76 votes per share, and the outstanding shares of Series B Preferred Stock collectively being entitled to 51% of all votes entitled to be cast. As a result, the Controlling Shareholder possesses voting control of the Company and may unilaterally determine the election of directors and substantially all matters requiring stockholder approval. The acquisition of control was effected pursuant to privately negotiated transactions contemplated by the Series A Share Purchase Agreement and the Series B Share Purchase Agreement, copies of which are filed as Exhibits 10.1 and 10.2 to this Current Report and incorporated herein by reference. The material terms of such transactions, including the consideration paid thereunder, are set forth in such agreements. Also on June 29, 2026, the Company entered into certain Debt Cancellation and Release Agreements with certain creditors of the Company pursuant to which certain outstanding indebtedness of the Company was compromised, settled, canceled, released, and extinguished. Copies of such Debt Cancellation and Release Agreements are filed as Exhibits 10.3 and 10.4 to this Current Report and incorporated herein by reference. The material terms of such transactions are set forth in such agreements. Porfirio Sanchez Talavera was appointed as Chief Executive Officer, Chairman of the Board, and a member of the Board of Directors of the Company. Aitan Zacharin resigned from all officer positions effective immediately upon such appointment and agreed to remain as a member of the Board of Directors solely until the expiration of the ten (10) day period required under Rule 14f-1. Upon expiration of such period, Mr. Zacharin’s resignation as a director will become effective and Mr. Sanchez Talavera will remain as the sole director of the Company.

9411998

Each share of Series A Convertible Preferred Stock is convertible into 50 shares of common stock and is entitled to vote 50 votes per share on all matters as a class with holders of common stock

0.94

5000 5000 30000 75000 200000 300000 The royalties for dietary supplement sales are 2.25% for net sales between $1-$10 million, 2.5% for net sales between $10 million and $50 million, and 3% for net sales between $50 million and $100 million. Royalty payments for dietary products are capped at $100 million in net sales. Royalties for drug products are 1% for net sales between $1 and $100 million, 1.5% for net sales between $100 million and $500 million, and 2% for net sales greater than $500 million. 0.12

1-for-1,500

0.001

0.503

1000

0.001

On June 29, 2026, the Controlling Shareholder entered into the Share Purchase. Through the Controlling Shareholder’s ownership of all outstanding shares of the Company’s Series A Preferred Stock and Series B Preferred Stock, Trafalgar Asset Management, LLC possesses approximately 96.62% of the aggregate voting power of the Company’s outstanding voting securities as of June 29, 2026, based upon 994,379 shares of Common Stock outstanding, each share of Series A Preferred Stock being entitled to 1.76 votes per share, and the outstanding shares of Series B Preferred Stock collectively being entitled to 51% of all votes entitled to be cast.

994379

Principles of Consolidation The consolidated financial statements include the accounts of Trafalgar International, Inc., and its wholly owned subsidiary Biocanrx, Inc. All intercompany balances and transactions have been eliminated in consolidation. TRAFALGAR INTERNATIONAL, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Six Months Ended June 30, 2026 and 2025 (Unaudited) NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Interim Financial Statements The interim financial statements as of June 30, 2026 are unaudited and have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission. These statements reflect all normal and recurring adjustments that, in the opinion of management, are necessary for a fair presentation of the information contained herein. Operating results for the six months ended June 30, 2026 are not necessarily indicative of results that may be expected for the year ending December 31, 2026. Certain information and finance disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to the Securities and Exchange Commission’s rules and regulations. These unaudited financial statements should be read in conjunction with our audited financial statements and notes for the year ended December 31, 2025 as included in our report on Form 10-K.

Cash and Cash Equivalents Investments having an original maturity of 90 days or less that are readily convertible into cash are considered to be cash equivalents. For the periods presented, the Company had no cash equivalents.

Notes and Accounts Receivable The Company maintains an allowance for doubtful accounts for estimated losses from the failure of its customers to make required payments for products and other consideration delivered. The Company estimates this allowance based on the age of the related receivable, knowledge of the financial condition of customers, review of historical receivables and reserve trends and other pertinent information. If the financial condition of customers deteriorates or an unfavorable trend in receivable collections is experienced in the future, additional allowances may be required. Historically, the Company’s reserves have approximated actual experience.

Income Taxes In accordance with Accounting Standards Codification (ASC) 740 - Income Taxes, the provision for income taxes is computed using the asset and liability method. The asset and liability method measures deferred income taxes by applying enacted statutory rates in effect at the balance sheet date to the differences between the tax basis of assets and liabilities and their reported amounts on the financial statements. The resulting deferred tax assets or liabilities are adjusted to reflect changes in tax laws as they occur. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized. We expect to recognize the financial statement benefit of an uncertain tax position only after considering the probability that a tax authority would sustain the position in an examination. For tax positions meeting a “more-likely-than-not” threshold, the amount to be recognized in the financial statements will be the benefit expected to be realized upon settlement with the tax authority. For tax positions not meeting the threshold, no financial statement benefit is recognized. As of June 30, 2026, we had no uncertain tax positions. We recognize interest and penalties, if any, related to uncertain tax positions as general and administrative expenses. We currently have no foreign federal or state tax examinations nor have we had any foreign federal or state examinations since our inception. To date, we have not incurred any interest or tax penalties.

Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.

Financial Instruments and Fair Value of Financial Instruments We follow ASC Topic 820, Fair Value Measurements and Disclosures, for assets and liabilities measured at fair value on a recurring basis. ASC Topic 820 establishes a common definition for fair value to be applied to existing US GAAP that requires the use of fair value measurements that establishes a framework for measuring fair value and expands disclosure about such fair value measurements. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC Topic 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below: TRAFALGAR INTERNATIONAL, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Six Months Ended June 30, 2026 and 2025 (Unaudited) NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">Level 1:</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Observable inputs such as quoted market prices in active markets for identical assets or liabilities</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2:</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Observable market-based inputs or unobservable inputs that are corroborated by market data</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3:</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions.</td></tr> </table> The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. Except for derivative liabilities, we had no financial assets or liabilities carried and measured on a recurring or nonrecurring basis during the reporting periods.

Derivative Liabilities We evaluate convertible notes payable, stock options, stock warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under the relevant sections of ASC Topic 815-40, Derivative Instruments and Hedging: Contracts in Entity’s Own Equity. The result of this accounting treatment could be that the fair value of a financial instrument is classified as a derivative instrument and is marked-to-market at each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income or other expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Financial instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815-40 are reclassified to a liability account at the fair value of the instrument on the reclassification date.

Long-lived Assets Long-lived assets such as property and equipment and intangible assets are periodically reviewed for impairment. We test for impairment losses on long-lived assets used in operations whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. Impairment evaluations involve management’s estimates on asset useful lives and future cash flows. Actual useful lives and cash flows could be different from those estimated by management which could have a material effect on our reporting results and financial positions. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. TRAFALGAR INTERNATIONAL, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Six Months Ended June 30, 2026 and 2025 (Unaudited) NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Equity Instruments Issued to Non-Employees for Acquiring Goods or Services Issuances of our common stock or warrants for acquiring goods or services are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The measurement date for the fair value of the equity instruments issued to consultants or vendors is determined at the earlier of (i) the date at which a commitment for performance to earn the equity instruments is reached (a “performance commitment” which would include a penalty considered to be of a magnitude that is a sufficiently large disincentive for nonperformance) or (ii) the date at which performance is complete. Although situations may arise in which counter performance may be required over a period of time, the equity award granted to the party performing the service may be fully vested and non-forfeitable on the date of the agreement. As a result, in this situation in which vesting periods do not exist if the instruments are fully vested on the date of agreement, we determine such date to be the measurement date and will record the estimated fair market value of the instruments granted as a prepaid expense and amortize such amount to expense over the contract period. When it is appropriate for us to recognize the cost of a transaction during financial reporting periods prior to the measurement date, for purposes of recognition of costs during those periods, the equity instrument is measured at the then-current fair values.

Related Parties A party is considered to be related to us if the party directly or indirectly or through one or more intermediaries, controls, is controlled by, or is under common control with us. Related parties also include our principal owners, our management, members of the immediate families of our principal owners and our management and other parties with which we may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. A party which can significantly influence the management or operating policies of the transacting parties, or if it has an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests, is also a related party. TRAFALGAR INTERNATIONAL, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Six Months Ended June 30, 2026 and 2025 (Unaudited) NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Revenue Recognition Revenue recognition: The Company adopted Accounting Standards Codification Topic 606, “Revenue from Contracts with Customers” (“ASC 606”) on January 1, 2018. In accordance with ASC 606, revenue is recognized when promised goods or services are transferred to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services, in accordance with the following five-step process: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif">Identify the contract(s) with a customer</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">●</td> <td style="font: 10pt Times New Roman, Times, Serif">Identify the performance obligations</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">●</td> <td style="font: 10pt Times New Roman, Times, Serif">Determine the transaction price</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">●</td> <td style="font: 10pt Times New Roman, Times, Serif">Allocate the transaction price</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">●</td> <td style="font: 10pt Times New Roman, Times, Serif">Recognize revenue when the performance obligations are met</td></tr> </table> The Company recognizes revenue from the sale of products when its performance obligation, consisting of the delivery of the purchased goods to the customer, has been satisfied and the customer takes possession. The Company had no revenue during the periods presented.

Advertising Costs Advertising costs are expensed as incurred. For the periods presented, we had no advertising costs.

Loss per Share We compute net income (loss) per share in accordance with FASB ASC 260, Earnings Per Share, which specifies the computation, presentation and disclosure requirements for earnings per share for entities with publicly held common stock. Basic net income (loss) per common share is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per common share is computed using the weighted average number of common shares outstanding during the period, adjusted for the effect of potentially dilutive securities, including convertible preferred stock, stock options, warrants and other convertible securities, when their inclusion would be dilutive. Potential common shares are excluded from the calculation of diluted net income (loss) per common share when their effect would be anti-dilutive. For the periods presented, shares issuable upon conversion of the Company’s Series A Convertible Preferred Stock were excluded from the calculation of diluted net income (loss) per common share because the effect of their inclusion would be anti-dilutive. As of June 30, 2026, the Company had no outstanding convertible notes payable to third parties (see Note E – Notes Payable to Third Parties) and no outstanding warrants (see Note G – Capital Stock and Warrants). TRAFALGAR INTERNATIONAL, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Six Months Ended June 30, 2026 and 2025 (Unaudited) NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Recently Enacted Accounting Standards In August 2020, the FASB issued ASU 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40)”. This ASU reduces the number of accounting models for convertible debt instruments and convertible preferred stock. As well as amend the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. In addition, this ASU improves and amends the related EPS guidance. This standard is effective for us on July 1, 2024, including interim periods within those fiscal years. Adoption is either a modified retrospective method or a fully retrospective method of transition. We are currently evaluating the impact of the adoption of ASU 2020-06 on our financial statements. In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-13, “Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”). Financial Instruments—Credit Losses (Topic 326) amends guideline on reporting credit losses for assets held at amortized cost basis and available-for-sale debt securities. For assets held at amortized cost basis, Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current estimate of all expected credit losses. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. For available-for-sale debt securities, credit losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance rather than as a write-down. ASU 2016-13 affects entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. The amendments in this ASU will be effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. We are currently evaluating the impact of the adoption of ASU 2016-13 on our financial statements. Other standards not presented are not deemed to be material.

NOTE B - GOING CONCERN Under ASC 205-40, we have the responsibility to evaluate whether conditions and/or events raise substantial doubt about our ability to meet our future obligations as they become due within one year after the date the financial statements are issued. As required by this standard, our evaluation shall initially not take into consideration the potential mitigating effects of our plans that have not been fully implemented as of the date the financial statements are issued. In performing the first step of this assessment, we concluded that the following conditions raise substantial doubt about our ability to meet our financial obligations as they become due. As of June 30, 2026, the Company had cash of $111, total current liabilities of $12,239, and negative working capital of $12,128. For the six months ended June 30, 2026, we incurred a net loss from operations of $44,931 and used $11,204 cash from operating activities. We expect to continue to incur negative cash flows until such time as our business generates sufficient cash inflows to finance our operations and debt service requirements. In performing the second step of this assessment, we are required to evaluate whether our plans to mitigate the conditions above alleviate the substantial doubt about our ability to meet our obligations as they become due within one year after the date that the financial statements are issued. Our future plans include securing additional funding sources. There is no assurance that sufficient funds required during the next year or thereafter will be generated from operations or that funds will be available through external sources. The lack of additional capital resulting from the inability to generate cash flow from operations or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material effect on the business. Furthermore, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significant dilutive effect on the Company’s existing shareholders. We have therefore concluded there is substantial doubt about our ability to continue as a going concern through June 2027. The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of the uncertainty related to our ability to continue as a going concern. TRAFALGAR INTERNATIONAL, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Six Months Ended June 30, 2026 and 2025 (Unaudited)

111

12239

-12128

-44931

-11204

NOTE C – RIGHT OF FIRST REFUSAL AGREEMENT On January 30, 2020, the Company executed a Right of First Refusal Agreement with an entity engaged in the business of cosmetics, health, and well-being. The Agreement provided for the Company to pay Kol Tuv Ventures, LLC (“KTV”), $<span id="xdx_900_eus-gaap--PaymentsForProceedsFromOtherInvestingActivities_c20200130__20200130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KolTuvVenturesLLCMember__us-gaap--TypeOfArrangementAxis__custom--RightOfFirstRefusalAgreementMember__srt--ProductOrServiceAxis__custom--CBDMember_znVq8ZP0goxc" title="Payment for other investment opportunities">25,000 on January 30, 2020 (which was paid January 30,2020) and to make other investments in opportunities to be pursued by KTV and/or payments to KTV to enable KTV to pursue and secure Cannabidiol (“CBD”) opportunities. The Agreement provides the Company an exclusive right of first refusal to participate in all CBD opportunities to be pursued by KTV for a term of five years. The $<span id="xdx_90A_eus-gaap--CostOfGoodsAndServicesSoldAmortization_c20200130__20200130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KolTuvVenturesLLCMember__us-gaap--TypeOfArrangementAxis__custom--RightOfFirstRefusalAgreementMember__srt--ProductOrServiceAxis__custom--CBDMember_zIXUBjpSGJai" title="Amortization cost">25,000 cost for this Agreement is being amortized over the five year term of the Agreement.

25000

NOTE D - LOANS PAYABLE TO RELATED PARTIES Loans payable to related parties consist of: SCHEDULE OF LOANS PAYABLE TO RELATED PARTIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20260630_zpM5009K3azc" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20251231_zMjkGoS7tMu7" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_409_eus-gaap--LoansPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ElishaKalfaAndYonahKalfaMember_z734jlIImcx" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Loans from Elisha Kalfa and Yonah Kalfa, holders of a total of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPQU5TIFBBWUFCTEUgVE8gUkVMQVRFRCBQQVJUSUVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--ConversionOfStockSharesConverted1_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ElishaKalfaAndYonahKalfaMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zcivo632DUac" title="Total number of shares convertible"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPQU5TIFBBWUFCTEUgVE8gUkVMQVRFRCBQQVJUSUVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ConversionOfStockSharesConverted1_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ElishaKalfaAndYonahKalfaMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zzFAIpL1C0d3" title="Total number of shares convertible">2,966,666 shares of Series A Convertible Preferred stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">180,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LoansPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AitanZacharinMember_zqL33u5gHOul" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Loan from Aitan Zacharin,CEO</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,600</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LoansPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FernandoBiskerAndSigalushLLCMember_zYeEvlVgxbta" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Loan from Fernando Bisker and Sigalush, LLC, holders of a total of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPQU5TIFBBWUFCTEUgVE8gUkVMQVRFRCBQQVJUSUVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--ConversionOfStockSharesConverted1_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FernandoBiskerAndSigalushLLCMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zKfWgTanlCyh" title="Total number of shares convertible"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPQU5TIFBBWUFCTEUgVE8gUkVMQVRFRCBQQVJUSUVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--ConversionOfStockSharesConverted1_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FernandoBiskerAndSigalushLLCMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z8Z0u4EKJihh" title="Total number of shares convertible">2,966,666 shares of Series A Convertible Preferred stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">80,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LoansPayableCurrent_iI_zvAtc6f3TTMf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">263,600</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> Pursuant to loan and contribution agreements dated July 31, 2018, the above loans are non-interest bearing and are to be repaid after the Company raises from investors no less than $<span id="xdx_90F_eus-gaap--RepaymentsOfRelatedPartyDebt_c20180730__20180731__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--LoanAndContributionAgreementsMember_zuBeZgkWc3nh" title="Repayments of related party debt">1,500,000 or generates sufficient revenue to make repayments (each, a “Replacement Event”). If the First Replacement Event does not occur within 18 months from July 31, 2018, the loans are to be repaid immediately. In the event there is insufficient capital to repay the loans, the lenders have the option to convert all or part of the loans into shares at the Company common stock at the average trading price of the 10 days prior to the date of the conversion request. TRAFALGAR INTERNATIONAL, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Six Months Ended June 30, 2026 and 2025 (Unaudited)

Loans payable to related parties consist of: SCHEDULE OF LOANS PAYABLE TO RELATED PARTIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20260630_zpM5009K3azc" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20251231_zMjkGoS7tMu7" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_409_eus-gaap--LoansPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ElishaKalfaAndYonahKalfaMember_z734jlIImcx" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Loans from Elisha Kalfa and Yonah Kalfa, holders of a total of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPQU5TIFBBWUFCTEUgVE8gUkVMQVRFRCBQQVJUSUVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--ConversionOfStockSharesConverted1_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ElishaKalfaAndYonahKalfaMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zcivo632DUac" title="Total number of shares convertible"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPQU5TIFBBWUFCTEUgVE8gUkVMQVRFRCBQQVJUSUVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ConversionOfStockSharesConverted1_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ElishaKalfaAndYonahKalfaMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zzFAIpL1C0d3" title="Total number of shares convertible">2,966,666 shares of Series A Convertible Preferred stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">180,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LoansPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AitanZacharinMember_zqL33u5gHOul" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Loan from Aitan Zacharin,CEO</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,600</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LoansPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FernandoBiskerAndSigalushLLCMember_zYeEvlVgxbta" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Loan from Fernando Bisker and Sigalush, LLC, holders of a total of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPQU5TIFBBWUFCTEUgVE8gUkVMQVRFRCBQQVJUSUVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--ConversionOfStockSharesConverted1_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FernandoBiskerAndSigalushLLCMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zKfWgTanlCyh" title="Total number of shares convertible"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPQU5TIFBBWUFCTEUgVE8gUkVMQVRFRCBQQVJUSUVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--ConversionOfStockSharesConverted1_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FernandoBiskerAndSigalushLLCMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z8Z0u4EKJihh" title="Total number of shares convertible">2,966,666 shares of Series A Convertible Preferred stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">80,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LoansPayableCurrent_iI_zvAtc6f3TTMf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">263,600</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

2966666

180000

3600

2966666

80000

263600

1500000

NOTE E - NOTES PAYABLE TO THIRD PARTIES Notes payable to third parties consist of: SCHEDULE OF NOTES PAYABLE TO THIRD PARTIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20260630_z4gt64iZ0Ga7" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20251231_zuMql9tQDtue" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr id="xdx_405_eus-gaap--NotesPayableCurrent_iI_hus-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zWeaFdSTZw7a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Promissory Note dated March 28, 2017 payable to John T. Root, Jr., interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20170328__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnT.RootMember_z7yB8RbvY959" title="Debt instrument, interest rate">4%, due <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_dd_c20170328__20170328__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnT.RootMember_zW6rf52aOixl" title="Debt instrument maturity date">September 28, 2017, convertible into shares of common stock at a conversion price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20170328__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnT.RootMember_zpHNlDn3cRp6" title=" Conversion price">.001 per share.</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">375</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--NotesPayableCurrent_iI_hus-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zVK2J9UJC8ci" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Convertible Promissory Note dated March 15, 2021 payable to FirstFire Global Opportunities Fund, LLC (“FF”), interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20210315__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_zAsLzWWX9Q6e" title="Debt instrumental Stated percentage">6%, due March 11, 2022-less unamortized debt discount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20260630__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_zd1f7dZLiJz1" title="Unamortized discount">0 and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20251231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_zIaiUVdPxq9" title="Unamortized discount">0, respectively. (i)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">171,062</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--NotesPayableCurrent_iI_zSoJej7v8kPb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">171,437</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">(i)</td><td style="width: 5pt"></td><td style="text-align: justify">On March 15, 2021, we issued a <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20210315__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_zuSNahX1UUMj" title="Debt instrument, interest rate">6% Convertible Promissory Note to FirstFire Global Opportunities Fund, LLC (“FF”), having a principal amount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20210315__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_zOajY4YmPfhh" title="Debt instrument, principal amount">545,000 and an initial tranche principal amount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90B_eus-gaap--ProceedsFromConvertibleDebt_c20210315__20210315__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_zrWqg48Tazq3" title="Proceeds from issuance of convertible debt">272,500 of which $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_eus-gaap--DebtInstrumentUnamortizedDiscountNoncurrent_iI_c20210315__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_zWZDhtKFGcqh" title="Debt conversion, original issue discount">22,500 constituted an original issue discount (the “FF Note”). In connection with the FF Note, we and FF entered into a registration rights agreement, three warrant agreements and a securities purchase agreement. On June 30, 2021, we issued the final tranche principle amount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90B_eus-gaap--ProceedsFromConvertibleDebt_c20210629__20210630__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zZEEsMW4P6Ae" title="Proceeds from issuance of convertible debt">272,500 of which $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--DebtInstrumentUnamortizedDiscountNoncurrent_iI_c20210630__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zbgCKcjvUvGl" title="Debt conversion, original issue discount">22,500 constituted an original issue discount (the “FF Note). The FF Note had an original maturity date of March 11, 2022, which was extended to April 30, 2023 by agreement between the parties dated May 1, 2022, which agreement also waiver certain defaults under the FF Note will mature on.</td> </tr></table> On June 1, 2022, the Company issued 25,000,000 shares for the conversion of $25,000 principal on the FirstFire note dated March 5, 2021 at a conversion price of $.001. During the three months ended September 30, 2022, the Company issued 135,000,000 shares for the conversion of $135,000 principal on the FirstFire note dated March 5, 2021 at a conversion price of $.001. During the three months ended December 31, 2022, the Company issued 64,000,000 shares for the conversion of $64,000 principal on the FirstFire note dated March 5, 2021 at a conversion price of $.001. During the three months ended March 31, 2025, the Company issued 80,000,000 shares for the conversion of $22,400 principal on the FirstFire note dated March 5, 2021 at a conversion price of $.00028 and 88,000,000 shares for the conversion of $37,680 principal on the FirstFire note dated March 5, 2021 at a conversion prices of $.00042. During the three months ended June 30, 2025, the Company issued 183,401 shares for the conversion of $97,200 principal on the FirstFire note dated March 5, 2021 at a conversion prices from $<span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20250630__us-gaap--DebtInstrumentAxis__custom--FirstFireNoteMember__srt--RangeAxis__srt--MinimumMember_zBrJLHmWVGt2" title="Conversion price">.00025 to $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20250630__us-gaap--DebtInstrumentAxis__custom--FirstFireNoteMember__srt--RangeAxis__srt--MaximumMember_z1CE9JE0WVBe" title="Conversion price">.0004. The FF Note may be pre-paid in whole or in part by paying FF the following premiums: SCHEDULE OF PREPAY AMOUNT AND DATE DESCRIPTION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify">PREPAY DATE</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify">PREPAY AMOUNT</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">≤ 30 days</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_90E_eus-gaap--DebtInstrumentDescription_c20260101__20260630__srt--StatementScenarioAxis__custom--LessThanOrEqualsToThirtyDaysMember__us-gaap--DebtInstrumentAxis__custom--FFNoteMember_zkwlquB7WeJ">105% * (Principal + Interest (“P+I”)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">31- 60 days</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">110% * (P+I)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">61-90 days</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">115% * (P+I)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">91-120 days</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_90B_eus-gaap--DebtInstrumentDescription_c20260101__20260630__srt--StatementScenarioAxis__custom--NinetyOneToHundredAndTwentyMember__us-gaap--DebtInstrumentAxis__custom--FFNoteMember_zIihYDQccbP3">120% * (P+I)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">121-150 days</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_90D_eus-gaap--DebtInstrumentDescription_c20260101__20260630__srt--StatementScenarioAxis__custom--OnehundredAndTwentyOneToOneHundredFiftyDaysMember__us-gaap--DebtInstrumentAxis__custom--FFNoteMember_zosMqEN2A4f1">125% * (P+I)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">151-180 days</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_908_eus-gaap--DebtInstrumentDescription_c20260101__20260630__srt--StatementScenarioAxis__custom--OneHundredAndFiftyOneToOneHundredAndEightyMember__us-gaap--DebtInstrumentAxis__custom--FFNoteMember_zbT95LIF8l52" title="PREPAY AMOUNT">130% * (P+I)</td></tr> </table> TRAFALGAR INTERNATIONAL, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Six Months Ended June 30, 2026 and 2025 (Unaudited) NOTE E - NOTES PAYABLE TO THIRD PARTIES (continued) Any amount of principal or interest on the FF Note, which is not paid when due shall bear interest at the rate of twenty-four (24%) per annum from the due date thereof until the same is paid (“Default Interest”). FF has the right beginning on the date which is the earlier of (i) the date the Registration Statement (as defined below) covering the shares issuable upon conversion of the FFG Notes is declared effective by the Securities and Exchange Commission (the “SEC”) or (ii) one hundred eighty (180) days following the Issue Date to convert all or any part of the outstanding and unpaid principal amount of the FF Note into fully paid and non-assessable shares of our common stock at the conversion price (the “Conversion Price”). The Conversion Price shall be, equal to 70% of the average closing price of our common stock for the five prior trading days prior to the date that a registration statement in respect of the shares into which is the FF Note is convertible is declared effective. The FF Note contains other customary terms found in like instruments for conversion price adjustments. In the case of an Event of Default (as defined in the Note), the FF Note shall become immediately due and payable in an amount (the “Default Amount”) equal to the principal amount then outstanding plus accrued interest (including any Default Interest) through the date of full repayment multiplied by one hundred twenty-five percent (125%) and interest shall accrue at the rate of Default Interest. Certain events of default will result in further penalties. Default obligations have been waived. On June 12, 2025, the Company and FirstFire agreed to amend and modify the note as follows: The Parties agree and acknowledge that as of the date hereof, the amount under due under the Note is $400,000, consisting of accrued but unpaid Default Interest and penalties as provided in the Note. The Parties agree that the Note shall continue to accrue Default Interest and penalties on the amounts due thereunder as provided in the Note and Lender shall be entitled to convert any amount due under the Note into shares of common stock of the Company (“Shares”) until the date the Company implements a proposed reverse split of its common stock at a ratio of 1 for 1,500 (the “Completion Date”), which has been approved by shareholders in compliance with applicable securities laws and regulation and is pending completion of review by the Financial Industry Regulatory Authority (“FINRA”) the Company’s Issuer Company-Related Action Notification Form submitted to FINRA on June 5, 2025. On the Completion Date, Lender agrees that the Note shall, without any further action, be deemed satisfied in full and to waive its rights to (a) receive payment of any amount due under the Note as of the Completion Date; (b) accrue Default Interest, penalties and any other amounts under the Note subsequent to the Completion Date; and (c) make any further conversions of amounts due under the Note. The Company completed the 1-for-1,500 reverse stock split in October 2025. Accordingly, pursuant to the June 12, 2025 amendment, the FF Note was deemed satisfied in full without further action, and FirstFire waived its rights to receive payment of any amounts remaining due under the FF Note, to accrue any additional Default Interest, penalties or other amounts, and to make any further conversions under the FF Note. As of June 30, 2026, no principal, accrued interest, Default Interest, penalties or other amounts remained outstanding under the FF Note, and FirstFire had no further conversion rights thereunder. Copies of Warrant A, Warrant B and Warrant C are attached as Exhibits 10.4, 10.5 and 10.6 to our current report on Form 8-K dated March 16, 2021. The valuation of the above warrants issued and recorded during the three months ended June 30, 2021 was $262,429. See NOTE -A -Nature of Operations (Debt Cancellation and Release Agreement)

Notes payable to third parties consist of: SCHEDULE OF NOTES PAYABLE TO THIRD PARTIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20260630_z4gt64iZ0Ga7" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20251231_zuMql9tQDtue" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr id="xdx_405_eus-gaap--NotesPayableCurrent_iI_hus-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zWeaFdSTZw7a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Promissory Note dated March 28, 2017 payable to John T. Root, Jr., interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20170328__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnT.RootMember_z7yB8RbvY959" title="Debt instrument, interest rate">4%, due <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_dd_c20170328__20170328__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnT.RootMember_zW6rf52aOixl" title="Debt instrument maturity date">September 28, 2017, convertible into shares of common stock at a conversion price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20170328__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnT.RootMember_zpHNlDn3cRp6" title=" Conversion price">.001 per share.</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">375</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--NotesPayableCurrent_iI_hus-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zVK2J9UJC8ci" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Convertible Promissory Note dated March 15, 2021 payable to FirstFire Global Opportunities Fund, LLC (“FF”), interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20210315__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_zAsLzWWX9Q6e" title="Debt instrumental Stated percentage">6%, due March 11, 2022-less unamortized debt discount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20260630__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_zd1f7dZLiJz1" title="Unamortized discount">0 and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20251231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_zIaiUVdPxq9" title="Unamortized discount">0, respectively. (i)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">171,062</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--NotesPayableCurrent_iI_zSoJej7v8kPb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">171,437</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">(i)</td><td style="width: 5pt"></td><td style="text-align: justify">On March 15, 2021, we issued a <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20210315__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_zuSNahX1UUMj" title="Debt instrument, interest rate">6% Convertible Promissory Note to FirstFire Global Opportunities Fund, LLC (“FF”), having a principal amount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20210315__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_zOajY4YmPfhh" title="Debt instrument, principal amount">545,000 and an initial tranche principal amount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90B_eus-gaap--ProceedsFromConvertibleDebt_c20210315__20210315__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_zrWqg48Tazq3" title="Proceeds from issuance of convertible debt">272,500 of which $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_eus-gaap--DebtInstrumentUnamortizedDiscountNoncurrent_iI_c20210315__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_zWZDhtKFGcqh" title="Debt conversion, original issue discount">22,500 constituted an original issue discount (the “FF Note”). In connection with the FF Note, we and FF entered into a registration rights agreement, three warrant agreements and a securities purchase agreement. On June 30, 2021, we issued the final tranche principle amount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90B_eus-gaap--ProceedsFromConvertibleDebt_c20210629__20210630__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zZEEsMW4P6Ae" title="Proceeds from issuance of convertible debt">272,500 of which $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--DebtInstrumentUnamortizedDiscountNoncurrent_iI_c20210630__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zbgCKcjvUvGl" title="Debt conversion, original issue discount">22,500 constituted an original issue discount (the “FF Note). The FF Note had an original maturity date of March 11, 2022, which was extended to April 30, 2023 by agreement between the parties dated May 1, 2022, which agreement also waiver certain defaults under the FF Note will mature on.</td> </tr></table>

0.04

2017-09-28

0.001

375

0.06

171062

171437

0.06

545000

272500

22500

272500

22500

25000000

25000

0.001

135000000

135000

0.001

64000000

64000

0.001

80000000

22400

0.00028

88000000

37680

0.00042

183401

97200

0.00025

0.0004

The FF Note may be pre-paid in whole or in part by paying FF the following premiums: SCHEDULE OF PREPAY AMOUNT AND DATE DESCRIPTION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify">PREPAY DATE</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify">PREPAY AMOUNT</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">≤ 30 days</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_90E_eus-gaap--DebtInstrumentDescription_c20260101__20260630__srt--StatementScenarioAxis__custom--LessThanOrEqualsToThirtyDaysMember__us-gaap--DebtInstrumentAxis__custom--FFNoteMember_zkwlquB7WeJ">105% * (Principal + Interest (“P+I”)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">31- 60 days</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">110% * (P+I)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">61-90 days</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">115% * (P+I)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">91-120 days</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_90B_eus-gaap--DebtInstrumentDescription_c20260101__20260630__srt--StatementScenarioAxis__custom--NinetyOneToHundredAndTwentyMember__us-gaap--DebtInstrumentAxis__custom--FFNoteMember_zIihYDQccbP3">120% * (P+I)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">121-150 days</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_90D_eus-gaap--DebtInstrumentDescription_c20260101__20260630__srt--StatementScenarioAxis__custom--OnehundredAndTwentyOneToOneHundredFiftyDaysMember__us-gaap--DebtInstrumentAxis__custom--FFNoteMember_zosMqEN2A4f1">125% * (P+I)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">151-180 days</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_908_eus-gaap--DebtInstrumentDescription_c20260101__20260630__srt--StatementScenarioAxis__custom--OneHundredAndFiftyOneToOneHundredAndEightyMember__us-gaap--DebtInstrumentAxis__custom--FFNoteMember_zbT95LIF8l52" title="PREPAY AMOUNT">130% * (P+I)</td></tr> </table>

105% * (Principal + Interest (“P+I”)

110% * (P+I)

115% * (P+I)

120% * (P+I)

125% * (P+I)

130% * (P+I)

(i) the date the Registration Statement (as defined below) covering the shares issuable upon conversion of the FFG Notes is declared effective by the Securities and Exchange Commission (the “SEC”) or (ii) one hundred eighty (180) days following the Issue Date to convert all or any part of the outstanding and unpaid principal amount of the FF Note into fully paid and non-assessable shares of our common stock at the conversion price (the “Conversion Price”).

In the case of an Event of Default (as defined in the Note), the FF Note shall become immediately due and payable in an amount (the “Default Amount”) equal to the principal amount then outstanding plus accrued interest (including any Default Interest) through the date of full repayment multiplied by one hundred twenty-five percent (125%) and interest shall accrue at the rate of Default Interest.

1.25

400000

1 for 1,500

1-for-1,500

262429

NOTE F - DERIVATIVE LIABILITY The derivative liability consists of: SCHEDULE OF DERIVATIVE LIABILITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_493_20260630_zuHDLb4doX55" style="border-bottom: Black 1pt solid; text-align: right">June 30, 2026</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_491_20251231_zvrU1jG2p1L1" style="border-bottom: Black 1pt solid; text-align: right">December 31, 2025</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DerivativeLiabilities_iI_hus-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zwmKiVtt8hxl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left; padding-bottom: 1pt">Convertible Promissory Note dated March 15, 2021 and June 30, 2021 payable to FirstFire Global Opportunities Fund, LLC, See Note E (i) Due <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIERFUklWQVRJVkUgTElBQklMSVRZIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20210629__20210630__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_zbd2NitKviY3" title="Debt instrument maturity date">March 11, 2022</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DerivativeLiabilities_iI_zBJelB9vi0h8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Total derivative liability</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> The Convertible Promissory Notes (the “Notes”) contain a variable conversion feature based on the future trading price of the Company’s common stock. Therefore, the number of shares of common stock issuable upon conversion of the Notes is indeterminate. The fair value of the derivative liability is measured at the respective issuance dates and quarterly thereafter using the Black Scholes option pricing model. Assumptions used for the calculation of the derivative liability of the Notes at December 31, 2020 were (1) stock price of $<span id="xdx_901_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uUSDPShares_c20201231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zFIDaBMsopnj" title="Derivative liability measurement input">.003 per share, (2) conversion price of $<span id="xdx_90D_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uUSDPShares_c20201231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputConversionPriceMember_zp8KIUhcoQfe" title="Derivative liability measurement input">.00169 per share, (3) term of <span id="xdx_908_ecustom--DerivativeLiabilityFairValueAssumptionsExpectedTerm_dtD_c20201231__20201231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z03XG3XJylzd" title="Derivative liability, measurement input, term">0 days, (4) expected volatility of <span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20201231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zmReZLufclKj" title="Derivative liability measurement input">142.94%, and (5) risk free interest rate of <span id="xdx_901_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20201231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zpdee5VSNpn6" title="Derivative liability measurement input">0%. Assumptions used for the calculation of the derivative liability of the Notes at March 31, 2021 were (1) stock price of $<span id="xdx_90C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uUSDPShares_c20210630__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zE5V9E0ZopLl" title="Derivative liability measurement input">.0011 per share, (2) conversion price of $<span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uUSDPShares_c20210630__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputConversionPriceMember_zomuWjbe0LLh" title="Derivative liability measurement input">.0071 per share, (3) term of <span id="xdx_90C_ecustom--DerivativeLiabilityFairValueAssumptionsExpectedTerm_dtD_c20210630__20210630__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zVThozrt9xDk" title="Derivative liability, measurement input, term">345 days, (4) expected volatility of <span id="xdx_90E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20210630__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zb4k8Mj4Iyah" title="Derivative liability measurement input">142.94%, and (5) risk free interest rate of <span id="xdx_90C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20210630__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zftRtcMAkA27" title="Derivative liability measurement input">.07%. As of June 30, 2021, the note no longer carries variable conversion features and as such, the derivative was reduced to zero. (i)As discussed in Note A above, warrants with “down round” features (and do not contain variable conversion features) are not subject to derivative liability treatment effective January 1, 2019. TRAFALGAR INTERNATIONAL, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Six Months Ended June 30, 2026 and 2025 (Unaudited)

The derivative liability consists of: SCHEDULE OF DERIVATIVE LIABILITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_493_20260630_zuHDLb4doX55" style="border-bottom: Black 1pt solid; text-align: right">June 30, 2026</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_491_20251231_zvrU1jG2p1L1" style="border-bottom: Black 1pt solid; text-align: right">December 31, 2025</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DerivativeLiabilities_iI_hus-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zwmKiVtt8hxl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left; padding-bottom: 1pt">Convertible Promissory Note dated March 15, 2021 and June 30, 2021 payable to FirstFire Global Opportunities Fund, LLC, See Note E (i) Due <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIERFUklWQVRJVkUgTElBQklMSVRZIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20210629__20210630__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_zbd2NitKviY3" title="Debt instrument maturity date">March 11, 2022</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DerivativeLiabilities_iI_zBJelB9vi0h8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Total derivative liability</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

2022-03-11

0.003

0.00169

P0D

142.94

0.0011

0.0071

P345D

142.94

0.07

NOTE G - CAPITAL STOCK AND WARRANTS Preferred Stock On July 31, 2018, The Greater Cannabis Company, Inc. (the “Company”) acquired <span id="xdx_903_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20180731__us-gaap--BusinessAcquisitionAxis__custom--GreenCCorporationMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zTCi5lBUnGoe" title="Percentage of issued and outstanding shares acquired">100% of the issued and outstanding shares of Class A common stock of Green C Corporation (“Green C”) in exchange for <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20180731__20180731__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--BusinessAcquisitionAxis__custom--GreenCCorporationMember_zmToOVKLzZF3" title="Shares issued in acquisition">9,411,998 newly issued shares of the Company’s Series A Convertible Preferred Stock (the “Exchange”). <span id="xdx_90B_eus-gaap--PreferredStockConversionBasis_c20180731__20180731__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--BusinessAcquisitionAxis__custom--GreenCCorporationMember_z3suI7FE2GFd" title="Preferred stock, conversion basis">Each share of Series A Convertible Preferred Stock is convertible into 50 shares of Common Stock and is entitled to 1.76 votes per share on all matters submitted to a vote of the holders of the Company’s capital stock, voting together with the holders of Common Stock and other voting securities as provided in the Company’s Articles of Incorporation, as amended.. On February 14, 2019, the Company issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20190214__20190214__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__dei--LegalEntityAxis__custom--EmetCapitalPartnersLLCMember_zud8Sf1wIRqk" title="Stock issued new issues">9,000,000 shares of Series B Convertible Preferred Stock to Emet Capital Partners, LLC (“Emet”) in exchange for the surrender of all outstanding warrants held by Emet. <span id="xdx_901_eus-gaap--PreferredStockConversionBasis_c20190214__20190214__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__dei--LegalEntityAxis__custom--EmetCapitalPartnersLLCMember_zcT1Clyjkk8k" title="Preferred stock, conversion basis">Each share of Series B Convertible Preferred Stock was convertible into one share of Company common stock subject to adjustment in case, at the time of conversion, the market price per share of the Company common stock was less than $<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20190214__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__dei--LegalEntityAxis__custom--EmetCapitalPartnersLLCMember_zLikKC3Va0fh" title="Debt instrument, convertible, conversion price">0.075 per share. On October 18, 2019, this exchange agreement was reversed. (See Note E) On September 21, 2021, <span id="xdx_904_eus-gaap--ConversionOfStockSharesIssued1_c20210921__20210921__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zSMr0ijunKS5" title="Conversion of stock, shares converted">300,000 shares of Series A Preferred Shares were converted into 15,000,000 shares of common stock. Designation of Series B Convertible Preferred Stock On October 22, 2025, the Company filed Articles of Amendment to its Articles of Incorporation with the Secretary of State of Florida creating a new class of <span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_pid_c20251022__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zRtMtz1PT7P1" title="Preferred stock, shares issued">1,000 shares of preferred stock, par value $<span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20251022__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z0Rlj3AnYaE3" title="Preferred stock, par value">0.001 per share, designated as Series B Convertible Preferred Stock (the “Series B Preferred Shares”). On October 22, 2025, the Company issued all <span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_pid_c20251022__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AitanZacharinMember_zXSozlaHmRjd" title="Preferred stock, shares issued">1,000 Series B Preferred Shares to Aitan Zacharin, then the Company’s Chief Executive Officer and sole director, in consideration of his waiver of $<span id="xdx_903_ecustom--StockIssuedDuringPeriodValueOfUnpaidCompensation_c20251022__20251022__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zSFi3ssF3vui" title="Unpaid compensation">20,000 in accrued but unpaid compensation due from the Company. On June 29, 2026, Trafalgar Asset Management, LLC, a Delaware limited liability company owned and controlled by Porfirio Sanchez Talavera, acquired all <span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20251022__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AitanZacharinMember_zzaDUIyWaPme" title="Preferred stock, shares outstanding">1,000 outstanding Series B Preferred Shares from Mr. Zacharin in connection with a change in control of the Company. Accordingly, as of June 30, 2026, Trafalgar Asset Management, LLC held all of the issued and outstanding Series B Preferred Shares and, by virtue of the voting rights associated with such shares, possessed voting control of the Company. The Series B Preferred Shares have the following rights, features, privileges and limitations (in pertinent part): TRAFALGAR INTERNATIONAL, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Six Months Ended June 30, 2026 and 2025 (Unaudited) NOTE G - CAPITAL STOCK AND WARRANTS (continued) Voting Rights. The Series B Preferred Shares vote together with shares of our common stock and our Series A Preferred Shares as a single class on all matters presented to a vote of holders of our capital stock, except as required by law. The Series B Preferred Shares entitle the holder thereof to 51.0% of the total voting power of the Company and to thereby control the Company’s business and affairs. In the event the Series B Preferred Shares are converted in part into shares of our common stock as set forth below or the holder transfers or seeks to transfer any of the Series B Preferred Shares to a third party, other than by the laws of descent and distribution, the super-voting rights described herein will terminate and the Series B Preferred Shares will vote on an “as converted basis” together with shares of our common stock and our Series A Preferred Shares as a single class on all matters presented to a vote of holders of our capital stock, except as required by law. Dividends. The Series B Preferred Shares do not have dividend rights. Liquidation, Dissolution, or Winding Up. Series B Preferred Shares will be entitled to a preference of $<span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20251022__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zloN5cCsLuOg" title="Preferred stock, par value">0.001 per share to shares of our common stock and Series B Preferred Shares in the event of a liquidation, dissolution or winding up of the Company. Conversion Rate and Adjustments. Conversion Rate. The Conversion Rate shall be <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251022__20251022__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zliKBCadxnt2" title="Number of shares issued">100,000 shares of common stock (as adjusted as provided for below) for each Series B Preferred Share. Adjustment for Stock Splits and Combinations. If the Company shall at any time or from time to time after the issuance of the Series B Preferred Shares effect a subdivision of the outstanding common stock, the Conversion Rate then in effect immediately before that subdivision shall be proportionately increased. If the Company shall at any time or from time to time after the issuance of the Series B Preferred Shares combine the outstanding shares of common stock, the conversion rate then in effect immediately before the combination shall be proportionately decreased. Any adjustment under this paragraph shall become effective at the close of business on the date the subdivision or combination becomes effective. Adjustment for Merger or Reorganization, etc. If there shall occur any reorganization, recapitalization, reclassification, consolidation, or merger involving the Company in which the common stock (but not the Series B Preferred Shares) is converted into or exchanged for securities, cash, or other property, then, following any such reorganization, recapitalization, reclassification, consolidation, or merger, each Series B Preferred Share shall thereafter be convertible in lieu of the common stock into which it was convertible prior to such event into the kind and amount of securities, cash or other property that a holder of the number of shares of common stock of the Company issuable upon conversion of one Series B Preferred Share immediately prior to such reorganization, recapitalization, reclassification, consolidation, or merger would have been entitled to receive pursuant to such transaction. Conversion. (a) Series B Preferred Shares are convertible into common stock at the option of the holder in whole or in part at any time at the conversion rate then in effect. (b) If so required by the Company, certificates surrendered for conversion shall be endorsed or accompanied by written instrument or instruments of transfer, in form satisfactory to the Company, duly executed by the registered holder or by his, her, or its attorney duly authorized in writing. As soon as practicable after a conversion and the surrender of the certificate or certificates for Series B Preferred Shares, the Company shall cause to be issued and delivered to such holder, or on his, her, or its written order, a certificate or certificates for the number of full shares of common stock issuable on such conversion and cash b) in respect of any fraction of a share of common stock otherwise issuable upon such conversion. (c) All certificates or other form of ownership evidencing shares of Series Preferred Shares (if any) that are required to be surrendered for conversion in accordance with the provisions hereof shall, from and after the date on which such preferred shares were converted, be deemed to have been retired and canceled and the shares of Series B Preferred Shares represented thereby converted into common stock for all purposes, notwithstanding the failure of the holder or holders thereof to surrender such certificates or other form of ownership on or prior to such date. Such converted Series B Preferred Shares may not be reissued as shares of such Series, and the Company may thereafter take such appropriate action (without the need for shareholder action) as may be necessary to reduce the authorized number of Series B Preferred Shares accordingly. TRAFALGAR INTERNATIONAL, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Six Months Ended June 30, 2026 and 2025 (Unaudited) NOTE G - CAPITAL STOCK AND WARRANTS (continued) Common Stock Effective March 10, 2017, in connection with a partial spin-off of the Company from Sylios Corp, the Company issued a total of 26,905,969 shares of its common stock. 5,378,476 shares were issued to Sylios Corp (representing <span id="xdx_901_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20170310__us-gaap--BusinessAcquisitionAxis__custom--SyliosCorpMember_zu4HqfvDxk8b" title="Business acquisition, percentage of voting interests acquired">19.99% of the issued and outstanding shares of Company common stock after the spin-off) and 21,527,493 shares were issued to the stockholders of record of Sylios Corp on February 3, 2017 on the basis of one share of Company common stock for each 500 shares of Sylios Corp common stock held (representing <span id="xdx_90F_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20170203__us-gaap--BusinessAcquisitionAxis__custom--SyliosCorpMember_z1gshwgOOoeh" title="Business acquisition, percentage of voting interests acquired">80.01% of the issued and outstanding shares of Company common stock after the spin-off). On January 4, 2019, the Company issued <span id="xdx_90C_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20190104__20190104__dei--LegalEntityAxis__custom--EmetCapitalPartnersLLCMember_zRR8J9WU3coh" title="Debt conversion, converted instrument, shares issued">769,785 shares of its common stock pursuant to a conversion of $670 principal and $100 accrued interest of its convertible note dated May 25, 2018 by Emet Capital Partners, LLC (“Emet”). This conversion was based on a conversion price of $<span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20190104__dei--LegalEntityAxis__custom--EmetCapitalPartnersLLCMember_zkX0L6TFjded" title="Debt instrument, convertible, conversion price">0.001 per share (rather than the Variable Conversion Price provided in the related note) submitted by Emet in its Conversion Notice. Emet asserted that the Company had committed a dilutive issuance, which triggered the “ratchet-down” provision of the related note which provides for a reduction of the conversion price. The $99,302 excess of the $100,072 fair value of the <span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20190101__20190331__dei--LegalEntityAxis__custom--EmetCapitalPartnersLLCMember_zasxtXcWxQWb" title="Debt conversion, converted instrument, shares issued">769,785 shares over the $<span id="xdx_902_ecustom--LossOnConversionOfNotePayableAndAccruedInterestToCommonStock_c20190101__20190331__dei--LegalEntityAxis__custom--EmetCapitalPartnersLLCMember_z66goyR9lFci" title="Loss on conversion of debt">770 liability reduction was charged to Loss on Conversion of Debt in the three months ended March 31, 2019. On January 4, 2019, the Company issued 695,129 shares of its common stock pursuant to an exercise of the equivalent of 1,400 warrants (of the 440,000 warrants issued to Emet Capital Partners, LLC on May 25, 2017) in a cashless exercise transaction based on a ratchet-down exercise price of $0.001 per share. On April 16, 2019, the Company issued 1,384,600 shares of its common stock pursuant to conversions of $40,500 principal and $7,961 accrued interest of two convertible notes issued to by Emet Capital Partners, LLC (“Emet”). The $131,537 excess of the $179,998 fair value of the 1,384,600 shares over the $<span id="xdx_90A_ecustom--LossOnConversionOfNotePayableAndAccruedInterestToCommonStock_c20190401__20190630__dei--LegalEntityAxis__custom--EmetCapitalPartnersLLCMember_z719jmiAvBu4" title="Loss on conversion of debt">47,961 liability reduction was charged to Loss on Conversion of Debt in the three months ended June 30, 2019. On May 29, 2019, the Company issued a total of <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20190529__20190529__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TwoConsultingFirmEntitiesMember_zUfntJLpxld4" title="Number of shares issued for services">542,000 shares of its common stock to two consulting firm entities for certain specified investor relations and advisory services. The $75,880 fair value of the 542,000 shares was charged to Other Operating Expenses in the three months ended June 30, 2019. TRAFALGAR INTERNATIONAL, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Six Months Ended June 30, 2026 and 2025 (Unaudited) NOTE G - CAPITAL STOCK AND WARRANTS (continued) On August 15, 2019, the Company issued 175,000 shares of its common stock to an entity consultant for accounting services rendered. The $12,250 fair value of the 175,000 shares was charged to Other Operating Expenses. On October 18, 2019, the Company entered into two Exchange Agreements with Emet Capital Partners, LLC (“Emet”). The first Exchange Agreement provided for the exchange of three outstanding convertible notes payable to Emet with a total remaining principal balance of $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20191018__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmetCapitalPartnersLLCMember__us-gaap--TypeOfArrangementAxis__custom--TwoExchangeAgreementMember_zidnCSRgvNWe" title="Debt instrument, face amount">20,399 and a total accrued interest balance of $<span id="xdx_909_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20191018__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmetCapitalPartnersLLCMember__us-gaap--TypeOfArrangementAxis__custom--TwoExchangeAgreementMember_znPEJ6eqogJg" title="Interest payable">5,189 for three new convertible notes payable to Emet in the total amount of $<span id="xdx_90B_eus-gaap--DebtInstrumentPeriodicPayment_c20191018__20191018__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmetCapitalPartnersLLCMember__us-gaap--TypeOfArrangementAxis__custom--TwoExchangeAgreementMember_zrDOMsJOIPgf" title="Debt instrument, periodic payment">25,587. The new notes bear interest at <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20191018__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmetCapitalPartnersLLCMember__us-gaap--TypeOfArrangementAxis__custom--TwoExchangeAgreementMember_znyftDTLkOxl" title="Debt instrument, interest rate, percentage">6%, are due on February 12, 2020 and are convertible into common stock at a conversion price equal to <span id="xdx_902_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_dp_uPure_c20191018__20191018__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmetCapitalPartnersLLCMember__us-gaap--TypeOfArrangementAxis__custom--TwoExchangeAgreementMember_zw1ONWWEHk76" title="Debt instrument, periodic payment">75% of the lowest Trading Price during the <span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_uInteger_c20191018__20191018__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmetCapitalPartnersLLCMember__us-gaap--TypeOfArrangementAxis__custom--TwoExchangeAgreementMember_z56dY0Es1xs4" title="Debt convertible threshold trading days">15 Trading Day Period prior to the Conversion Date. The second Exchange Agreement provided for the reversal of the February 14, 2019 exchange agreement pursuant to which certain warrants then held by Emet were exchanged for <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20190214__20190214__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmetCapitalPartnersLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecondExchangeAgreementMember_zvwo2C5IBaR5" title="Stock issued new issues">9,000,000 shares of Series B Convertible Preferred Stock (see Note G) and the exchange of such warrants for four new convertible notes payable to Emet in the total amount of $<span id="xdx_900_eus-gaap--DebtInstrumentPeriodicPayment_c20190214__20190214__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmetCapitalPartnersLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecondExchangeAgreementMember_zE6yiEjkTvg2" title="Debt instrument, periodic payment">675,000. These new note bear interest at <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20190214__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmetCapitalPartnersLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecondExchangeAgreementMember_zinkEcN4auc9" title="Debt instrument, interest rate, percentage">2%, are due on October 18, 2020 and are convertible into common stock at a conversion price equal to <span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_dp_uPure_c20190214__20190214__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmetCapitalPartnersLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecondExchangeAgreementMember_zZgkp7X8BSgb" title="Debt instrument, interest rate, percentage">75% of the lowest Trading Price during the <span id="xdx_905_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_uInteger_c20190214__20190214__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmetCapitalPartnersLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecondExchangeAgreementMember_zz7JxGKydIPl" title="Debt convertible threshold trading days">15 Trading Day Period prior to the Conversion Date. On November 11, 2019, the Company issued 1,748,363 shares of its common stock pursuant to a conversion of $53,705 principal and $2,680 accrued interest and fees of its convertible note dated October 18, 2019 by Emet. On December 20, 2019, the Company issued 1,468,204 shares of its common stock pursuant to a conversion of $29,000 principal and $4,015 accrued interest and fees of its convertible note dated October 18, 2019 by Emet. On December 24, 2019, the Company issued 637,273 shares of its common stock pursuant to a conversion of $10,000 principal and $515 accrued interest and fees of its convertible note dated October 18, 2019 by Emet. During the three months ended March 31, 2020, the Company issued a total of <span id="xdx_90E_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20200101__20200331__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zIRoaePVker5" title="Debt conversion, converted instrument, shares issued">21,484,688 shares of common stock pursuant to conversions of an aggregate of $165,350 in principal and $11,793 in interest under our outstanding convertible notes. The $228,949 excess of the $406,093 fair value of the 21,484,688 shares of common stock at the respective dates of issuance over the $177,143 liability reduction was charged to Loss on Conversions of Notes Payable. During the three months ended June 30, 2020, the Company issued a total of <span id="xdx_90D_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20200401__20200630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zitaR1Y4TP7e" title="Debt conversion, converted instrument, shares issued">27,563,525 shares of common stock pursuant to conversions of an aggregate of $67,082 in principal and $10,613 in interest under our outstanding convertible notes. The $132,838 excess of the $210,532 fair value of the 27,563,525 shares of common stock at the respective dates of issuance over the $77,695 liability reduction was charged to Loss on Conversions of Notes Payable. During the three months ended September 30, 2020, the Company issued a total of <span id="xdx_908_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20200701__20200930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zdw2Z49unDah" title="Debt conversion, converted instrument, shares issued">115,277,834 shares of common stock pursuant to conversions of an aggregate of $311,050 in principal and $18,462 in interest under our outstanding convertible notes. The $467,554 excess of the $797,067 fair value of the 115,277,834 shares of common stock at the respective dates of issuance over the $329,512 liability reduction was charged to Loss on Conversions of Notes Payable. During the three months ended December 31, 2020, the Company issued a total of <span id="xdx_903_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20201001__20201231__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zcP8Cyl0PwGi" title="Debt conversion, converted instrument, shares issued">261,215,948 shares of common stock pursuant to conversions of an aggregate of $325,212 in principal and $16,849 in interest under our outstanding convertible notes. The $462,263 excess of the $804,324 fair value of the 261,215,948 shares of common stock at the respective dates of issuance over the $342,061 liability reduction was charged to Loss on Conversions of Notes Payable. During the three months ended March 31, 2021, the Company recorded the conversion of note payable ($22,500) and accrued interest ($814) into <span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210101__20210630__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember_zpHpv7BNtZsi" title="Debt conversion, converted instrument, shares issued">13,795,118 shares of common stock (Fair Value of $<span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210101__20210630__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember_zJYwa0gOLosj" title="Debt conversion, converted instrument, amount">45,525). TRAFALGAR INTERNATIONAL, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Six Months Ended June 30, 2026 and 2025 (Unaudited) NOTE G - CAPITAL STOCK AND WARRANTS (continued) During the three months ended June 30, 2021, the Company recorded the value of the warrants at $262,429 and the conversion of the second FirstFire note tranche in the amount of $<span id="xdx_90D_eus-gaap--DebtConversionOriginalDebtAmount1_pp0p0_c20210401__20210630__us-gaap--DebtInstrumentAxis__custom--SecondFirstFireNoteMember_zyEzlfG4tDAl" title="Debt conversion, original debt, amount">39,000. On July 15, 2021, the Company issued <span id="xdx_90D_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210715__20210715__us-gaap--DebtInstrumentAxis__custom--FirstFireNoteMember_zVzjusL45Mfa" title="Debt conversion, converted instrument, shares issued">10,000,000 shares for the conversion of $52,080 principal on the FirstFire note dated March 5, 2021 at a conversion price of $<span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20210715__us-gaap--DebtInstrumentAxis__custom--FirstFireNoteMember_zuSzhHfZX6U5" title="Debt instrument, convertible, conversion price">.005208. On June 1, 2022, the Company issued <span id="xdx_90C_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20220601__20220601__us-gaap--DebtInstrumentAxis__custom--FirstFireNoteMember_zOGVQMw1S4Bd" title="Debt conversion, converted instrument, shares issued">25,000,000 shares for the conversion of $25,000 principal on the FirstFire note dated March 5, 2021 at a conversion price of $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20220601__us-gaap--DebtInstrumentAxis__custom--FirstFireNoteMember_zyo9iY11SEd1" title="Debt instrument, convertible, conversion price">.001. During the three months ended September 30, 2022, the Company issued <span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20220701__20220930__us-gaap--DebtInstrumentAxis__custom--FirstFireNoteMember_z2kjxeUo3nKe" title="Number of conversion share issued">135,000,000 shares for the conversion of $135,000 principal on the FirstFire note dated March 5, 2021 at a conversion price of $.001. During the three months ended December 31, 2022, the Company issued <span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20221001__20221231__us-gaap--DebtInstrumentAxis__custom--FirstFireNoteMember_zAKSGIYKdMQ4" title="Number of conversion share issued">64,000,000 shares for the conversion of $64,000 principal on the FirstFire note dated March 5, 2021 at a conversion price of $.001. During the year ended December 31, 2023, the Company issued <span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--FirstFireNoteMember_zXHnmUH2SmZd" title="Number of conversion share issued">72,000,000 shares for the conversion of $72,000 principal on the FirstFire note dated March 5, 2021 at a conversion price of $.001. During the three months ended March 31, 2025, the Company issued <span id="xdx_908_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20250101__20250331__us-gaap--DebtInstrumentAxis__custom--FirstFireNoteOneMember_zlgpRXH9mgV5" title="Number of conversion share issued">80,000,000 shares for the conversion of $22,400 principal on the FirstFire note dated March 5, 2021 at a conversion price of $.00028 and <span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20250101__20250331__us-gaap--DebtInstrumentAxis__custom--FirstFireNoteTwoMember_zFCzDBTXRBdc" title="Number of conversion share issued">88,000,000 shares for the conversion of $<span id="xdx_90B_eus-gaap--DebtConversionConvertedInstrumentAmount1_pp0p0_c20250101__20250331__us-gaap--DebtInstrumentAxis__custom--FirstFireNoteTwoMember_zwYnJ1mpX78e" title="Principal amount debt conversion">37,680 principal on the FirstFire note dated March 5, 2021 at a conversion prices of $.00042. On February 17, 2025, the Company issued 2,250,000 shares of common stock for compensation valued at $ 1,800. On April 3, 2025, the Company issued 66,691 shares of common stock at $.0001 for accrued compensation valued at $10,000. During the three months ended June 30, 2025, the Company issued <span id="xdx_90B_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20250401__20250630__us-gaap--DebtInstrumentAxis__custom--FirstFireNoteMember_z7G4S7hGB6Nj" title="Number of conversion share issued">183,401 shares for the conversion of $97,200 principal on the FirstFire note dated March 5, 2021 at conversion prices from $<span id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20250630__us-gaap--DebtInstrumentAxis__custom--FirstFireNoteMember__srt--RangeAxis__srt--MinimumMember_zx3evaEmmyel" title="Conversion price">.00025 to $<span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20250630__us-gaap--DebtInstrumentAxis__custom--FirstFireNoteMember__srt--RangeAxis__srt--MaximumMember_zCkLeFwevNw6" title="Conversion price">.0004. The Company implemented a 1-for-1,500 Reverse Split of the Company’s common stock (the “Reverse Split”) effective as of the close of business on October 15, 2025. As a result, every <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesStockSplits_pid_c20251015__20251015__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zW4SoPLa75Yh" title="Reverse stock split shares">1,500 pre-Reverse Split shares of common stock outstanding will automatically combine into one new share of post-Reverse Split common stock without any action on the part of the holders. The Company’s common stock will begin trading on a post-Reverse Split basis at the opening of trading on Thursday, October 16, 2025. In connection therewith, the Company’s ticker symbol will be GCAND for twenty (20) trading days to designate that it is trading on a post-Reverse Split basis. In addition, our post-Reverse Split common stock will trade under the new CUSIP Number 391657202. Following the Reverse Split, the number of shares of the Company’s issued and outstanding Common Stock was reduced from <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesStockSplits_pid_c20251015__20251015__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MaximumMember_zgwRsLSfWls6">1,349,888,436 shares to approximately <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesStockSplits_pid_c20251015__20251015__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MinimumMember_zYNa0T92FQv8">900,256 shares. No fractional shares of Common Stock were issued as a result of the Reverse Split. Instead, the Company issued one whole share of post-Reverse Split Common Stock to any stockholder who otherwise would have received a fractional share as a result of the Reverse Split. The number of authorized shares of Common Stock remained unaffected, and the par value remained $0.001 per share.. In connection with the reverse stock split, we filed Articles of Amendment to our Articles of Incorporation with the Secretary of State of Florida, a copy of which is included as Exhibit 35.1 to this Report. On October 22, 2025, the Company issued 44,679 shares of common stock for the conversion of $13,400 principal on the FirstFire note dated March 5, 2021 at a conversion price of $<span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20251022__us-gaap--DebtInstrumentAxis__custom--FirstFireNoteMember_z1uPm3rcQ39d" title="Debt instrument, convertible, conversion price">.0002. During the second quarter 2026, the Company issued 49,444 shares of common stock for accrued compensation. TRAFALGAR INTERNATIONAL, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Six Months Ended June 30, 2026 and 2025 (Unaudited) NOTE G - CAPITAL STOCK AND WARRANTS (continued) Warrants On March 11, 2021, in connection with the issuance of a Convertible Promissory Note to FirstFire Global Opportunities Fund, LLC (“FF”) (see Note E), the Company issued three warrants to FF: Warrant A to purchase <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210311__us-gaap--StatementEquityComponentsAxis__custom--WarrantAMember__dei--LegalEntityAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_zv5GYF8l2cV1" title="Warrant purchase of common stock">25,000,000 shares of Common Stock at an exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210311__us-gaap--StatementEquityComponentsAxis__custom--WarrantAMember__dei--LegalEntityAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_zE1ZEHkh5EB2" title="Exercise price of warrants">0.025 per share; Warrant B to purchase <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210311__us-gaap--StatementEquityComponentsAxis__custom--WarrantBMember__dei--LegalEntityAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_zmtvrsR0BZ9i" title="Warrant purchase of common stock">15,000,000 shares of Common Stock at an exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210311__us-gaap--StatementEquityComponentsAxis__custom--WarrantBMember__dei--LegalEntityAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_zzkcx16iLaBk" title="Exercise price of warrants">0.05 per share; and Warrant C to purchase <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210311__us-gaap--StatementEquityComponentsAxis__custom--WarrantCMember__dei--LegalEntityAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_z5MMe48A6zR" title="Warrant purchase of common stock">10,000,000 shares of Common Stock at an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210311__us-gaap--StatementEquityComponentsAxis__custom--WarrantCMember__dei--LegalEntityAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_zGXKd21NfKv5" title="Exercise price of warrants">0.075 per share. Each of Warrant A, Warrant B and Warrant C had an expiration date of September 11, 2022. The warrants were valued at $<span id="xdx_909_eus-gaap--WarrantsAndRightsOutstanding_iI_c20210630__us-gaap--StatementEquityComponentsAxis__custom--WarrantAMember__dei--LegalEntityAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_z6UCqbQOeoll" title="Warrants issued value">262,429 when issued during the three months ended June 30, 2021. Copies of Warrant A, Warrant B and Warrant C were filed as Exhibits 10.4, 10.5 and 10.6, respectively, to the Company’s Current Report on Form 8-K dated March 16, 2021. Warrant A, Warrant B and Warrant C expired by their terms on September 11, 2022. As of June 30, 2026, none of such warrants remained outstanding or exercisable, and the Company had no outstanding warrants.

9411998

Each share of Series A Convertible Preferred Stock is convertible into 50 shares of Common Stock and is entitled to 1.76 votes per share on all matters submitted to a vote of the holders of the Company’s capital stock, voting together with the holders of Common Stock and other voting securities as provided in the Company’s Articles of Incorporation, as amended

9000000

Each share of Series B Convertible Preferred Stock was convertible into one share of Company common stock subject to adjustment in case, at the time of conversion, the market price per share of the Company common stock was less than $0.075 per share.

0.075

300000

15000000

1000

0.001

1000

20000

1000

0.510

0.001

100000

26905969

5378476

0.1999

21527493

500

0.8001

769785

670

100

0.001

99302 100072

769785

770

695129

1400 440000

0.001

1384600

40500

7961

131537 179998

1384600

47961

542000

75880 542000

175000

12250

175000

20399

5189

25587

0.06

0.75

9000000

675000

0.02

0.75

1748363

53705

2680

1468204

29000

4015

637273

10000

515

21484688

165350

11793

228949

406093

21484688

177143

27563525

67082

10613

132838

210532

27563525

77695

115277834

311050

18462

467554

797067

115277834

329512

261215948

325212

16849

462263

804324

261215948

342061

22500

814

13795118

45525

262429

39000

10000000

52080

0.005208

25000000

25000

0.001

135000000

135000

0.001

64000000

64000

0.001

72000000

72000

0.001

80000000

22400

0.00028

88000000

37680

0.00042

2250000

1800

66691 0.0001 10000

183401

97200

0.00025

0.0004

1-for-1,500

1500

1349888436

900256

0.001

44679

13400

0.0002

49444

25000000

0.025

15000000

0.05

10000000

0.075

262429

NOTE H - INCOME TAXES The Company and its United States subsidiaries file consolidated Federal income tax returns. Green C Corporation, its Ontario Canada subsidiary, files Canada and Ontario income tax returns. At June 30, 2026 the Company has available for federal income tax purposes a net operating loss carry forward that may be used to offset future taxable income. The Company has provided a valuation reserve against the full amount of the net operating loss benefit, since in the opinion of management based upon the earnings history of the Company, it is not more likely than not that the benefits will be realized. If there are significant changes in the Company’s ownership, the future use of its existing net operating losses will be limited. All tax years of the Company and its United States subsidiaries remain subject to examination by the Internal Revenue Service. TRAFALGAR INTERNATIONAL, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Six Months Ended June 30, 2026 and 2025 (Unaudited)

NOTE I - COMMITMENTS AND CONTINGENCIES Pharmedica Exclusive License Agreement On June 21, 2018, Green C executed an Exclusive License Agreement with Pharmedica, Ltd. (“Pharmedica”), an Israeli company, to exploit certain Pharmedica intellectual property for the development and distribution of a certain Licensed Product involved in the transmucosal delivery of medicinal or recreational cannabis. The agreement provides for Green C payments to Pharmedica of a $<span id="xdx_906_eus-gaap--DirectTaxesAndLicensesCosts_c20180621__20180621__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GreenCCorporationMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zz0cD4Kubwpb" title="Cost, direct tax and license">100,000 license fee (which was paid by 2591028 Ontario Limited, an entity affiliated with Green C’s Chief Executive Officer, on June 26, 2018) and annual royalties at a rate of <span id="xdx_904_ecustom--AnnualRoyaltiesRate_pid_dp_uPure_c20180621__20180621__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GreenCCorporationMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zZJ19Tj687u3" title="Annual royalties rate">5% of the Net Sales of the Licensed Product subject to a Minimum Annual Royalty of $<span id="xdx_90A_eus-gaap--RoyaltyExpense_c20180621__20180621__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GreenCCorporationMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zHUbYNA9HaI2" title="Royalty expense">50,000. The agreement also provides for certain milestones to be accomplished by Green C in order for Green C to retain the license. Green C and Pharmedica each may terminate the agreement upon the occurrence of a material breach by the other party of its obligations under the agreement and such other party’s failure to remedy such breach to the reasonable satisfaction of the other party within thirty (30) days after being requested in writing to do so. The Company generated only minimal revenues from this asset through December 31, 2019 and did not pay the Year 1 Minimum Annual Royalty of $50,000 due Pharmedica. Accordingly, we recorded an impairment charge of $69,749 at December 31, 2019 and reduced the $69,749 remaining carrying value of this intangible asset to $0. On September 2, 2020, Green C notified Pharmedica of Green C’s termination of the Exclusive License Agreement and Green C’s intention to wind up Green C. On September 17, 2020, Pharmedica notified Green C of Pharmedica’s acceptance of Green C’s proposal to terminate the license agreement and Pharmedica’s intention not to burden Green C further. Accordingly, we recorded “Forgiveness of Royalty Payable” other income of $<span id="xdx_901_ecustom--ForgivenessOfRoyaltyPayable_c20200701__20200930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GreenCCorporationMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_z5GASKClZvs2" title="Forgiveness of royalty payable">50,000 in the three months ended September 30, 2020 and reduced the $<span id="xdx_905_ecustom--ForgivenessOfRoyaltyPayable_c20200701__20200930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GreenCCorporationMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zm0QSkIxrlya" title="Forgiveness of royalty payable">50,000 “Accrued Royalties” liability balance to $<span id="xdx_902_eus-gaap--AccruedRoyaltiesCurrentAndNoncurrent_iI_c20200930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GreenCCorporationMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zs9L4r4PjS41" title="Accrued royalties">0. Sub-License Agreement with Symtomax Unipessoal Lda On July 15, 2019, the Company executed a Sub-License Agreement with Symtomax Unipessoal Lda (“Symtomax”). The agreement provides for the Company’s grant to Symtomax of a non-exclusive right and sub-license to use certain Company technology and intellectual property to develop and commercialize products for sale in Europe, the Middle East, and Africa. The agreement provides for Symtomax payments of royalties to the Company (payable monthly) ranging from <span id="xdx_907_ecustom--AnnualRoyaltiesRate_pid_dp_c20190715__20190715__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--SubLicenseAgreementMember__dei--LegalEntityAxis__custom--SymtomaxUnipessoalLdaMember_zXGtkEnC8oMi" title="Annual royalties rate">10% to <span id="xdx_902_ecustom--AnnualRoyaltiesRate_pid_dp_c20190715__20190715__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--SubLicenseAgreementMember__dei--LegalEntityAxis__custom--SymtomaxUnipessoalLdaMember_zVUFEqJlWezl" title="Annual royalties rate">17% of Symtomax sales of eluting patches developed from Company technology. On May 27, 2020, the Company executed an amended and restated sub-license agreement with Symtomax (the “Amended License Agreement”). The term of the Amended License Agreement ends the earlier of (i) August 31, 2021 and (ii) the date that Symtomax is no longer commercializing any of the products. The term is extended for an additional year on each anniversary of the agreement for any country where the royalty payment in respect of such country was equal to or greater than $<span id="xdx_906_eus-gaap--PaymentsForRoyalties_c20200527__20200527__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--SubLicenseAgreementMember__dei--LegalEntityAxis__custom--SymtomaxUnipessoalLdaMember_zjmsIGo80w9g" title="Payments for royalties">1,000,000 for the previous year. To date, Symtomax has not made any sales requiring the payment of royalties to the Company. Agreements On July 31, 2018, the Company executed Services Agreements with its newly appointed Chief Executive Officer (the “CEO”), for terms of five years. The Agreement provides for a monthly base salary of $<span id="xdx_908_eus-gaap--OfficersCompensation_c20180731__20180731__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--ServicesAgreementsMember_zeHANZo1bek4" title="Officers compensation">10,000 for the CEO. For the six months ended June 30, 2026 and 2025 the Company expensed a total of $30,000 and $60,000, respectively. See Note-A-Nature of Operations - Change in Control.

100000

0.05

50000

69749

50000 50000

0.10 0.17

1000000

10000

30000

60000

NOTE J-RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS The Company restated the consolidated financial statements for the three months ended March 31, 2025 (which were previously included in the Company’s Form 10-Q filed with the SEC on May 12, 2025) in order to correct the terms of the note agreement to FirstFire. (see Note-E-NOTES PAYABLE TO THIRD PARTIES) As restated, the default of penalties and interest was recorded as of March 31, 2025 in the amount of $ 138,906. In the second quarter ended June 30, 2025, all default penalties and interest were eliminated according to agreements per both parties.

138906

NOTE K – SUBSEQUENT EVENTS On July 29, 2026, the Board of Directors appointed Carlos Septién as Chief Operating Officer, Michelle Cervantes Vivanco as Chief Financial Officer, and Ernesto Gómez Berjón as Chief Growth Officer. Mr. Septién, Ms. Cervantes Vivanco and Mr. Gómez Berjón were also appointed as members of the Company’s Board of Directors. Porfirio Sanchez Talavera continues to serve as the Company’s Chief Executive Officer, Chairman of the Board of Directors and a director. Also on July 29, 2026, the Company filed Articles of Amendment with the Florida Secretary of State changing its corporate name from The Greater Cannabis Company, Inc. to Trafalgar International, Inc. The Company has submitted the related corporate action to the Financial Industry Regulatory Authority (“FINRA”) for processing. Pending completion of the FINRA corporate action, the Company’s common stock continues to trade under the symbol “GCAN.”

On March 15, 2021, we issued a 6% Convertible Promissory Note to FirstFire Global Opportunities Fund, LLC (“FF”), having a principal amount of $545,000 and an initial tranche principal amount of $272,500 of which $22,500 constituted an original issue discount (the “FF Note”). In connection with the FF Note, we and FF entered into a registration rights agreement, three warrant agreements and a securities purchase agreement. On June 30, 2021, we issued the final tranche principle amount of $272,500 of which $22,500 constituted an original issue discount (the “FF Note). The FF Note had an original maturity date of March 11, 2022, which was extended to April 30, 2023 by agreement between the parties dated May 1, 2022, which agreement also waiver certain defaults under the FF Note will mature on.